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Abstract 
Title of the abstract:  “A pilot study to look at the effect of IL-28B polymorphism on IL-
28 expression and immunological recovery among HIV-1 infected individuals following 
Antiretroviral Therapy” 
Department: Department of Clinical Microbiology 
Name of the candidate: Dr. Srinidhi B V 
Degree and subject: M.D Microbiology 
Name of the guide: Dr. Rajesh K. 
Objectives: 
To look at the frequency of IL-28B polymorphisms in south Indian HIV infected individuals 
and its effect on IL-28 plasma level and immunological recovery following ART.   
Methods: 
A total of 49 HIV infected individuals and 30 healthy controls were recruited. Whole 
blood samples were collected before and after 6-9 months of ART from patients. Absolute 
CD4+/CD8+ T cell counts, CD3+cell counts and CD4/CD8 ratio were estimated using flow 
cytometry (FACS Count). IL-28B polymorphism at rs12979860 and rs8099917 were detected 
by PCR-RFLP and IL-28B plasma level estimation was done by ELISA. Association between 
polymorphism, cell counts and IL-28 plasma level were analyzed.  
Results: 
There was significant association of CC genotype at rs12979860 (p=0.03) and CC/TT 
haplotype (p=0.03) with higher CD4+T-cell count among treatment naïve HIV infected 
individuals. There was a significant (p=0.03) association of CC/TT haplotype with increase 
in CD4/CD3% following ART. There was no correlation (p=>0.05) between IL-28B plasma 
level with IL-28B polymorphism, CD4+ T cell and CD4/CD8 ratio.  There was no significant 
difference in the frequencyof polymorphism and IL-28B plasma level between HIV infected 
individuals and healthy controls. The CT/GT haplotype had a significant higher IL-28B 
plasma level compared to wild type CC/TT before the initiation of ART and significantly 
higher decrease observed in CT/GT haplotype compared to CC/TT wild type were significant 
 
Conclusion: 
In conclusion our preliminary data from this pilot study showed significantly higher CD4+ T-
cells among HIV infected individuals with wild haplotype (CC/TT) prior to ART and 
significantly high CD4+ T cells and CD4/CD3% following ART. This study showed no 
association of IL-28B polymorphism with IL-28B plasma level and CD4+T cell count or 
CD4/CD8 ratio.  Since IFNλ is a powerful immune modulator functional studies are 
warranted to understand the IFNλ mediated immuno-pathogeneis in HIV infection.  
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AIMS AND OBJECTIVES 
 
1) HYPOTHESIS 
The IL-28 gene polymorphism(s) will enhance the expression of the interleukin-28 and the 
recovery of CD4+ T- cell following ART among HIV-1 infected individuals 
 
2) AIM 
To study the frequency and distribution of IL28B polymorphisms and its influence of IL28B 
plasma level and immunological recovery in HIV infected individuals following 6-9 months 
of Antiretroviral Therapy.  
 
 
3) OBJECTIVES  
1) To look at the frequency of IL-28B polymorphisms in HIV infected individuals and 
healthy controls. 
2) To determine the IL-28B plasma level in the treatment naive HIV infected individual 
and healthy controls. 
3) To determine the IL-28B plasma level in HIV infected individuals following ART. 
4) To look at any association of IL-28B plasma level in HIV infected individuals 
including those presenting with Immune Reconstitution Inflammatory Syndrome 
(IRIS) following ART. 
5) To analyze the association of IL-28B polymorphism with plasma level of IL-28B and 
immunological recovery (% increase in CD4+ T cells) following ART among HIV-1 
infected individuals. 
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1. Introduction 
Infection with human immunodeficiency virus-1 (HIV-1) continues to be the major causes of 
morbidity and mortality. HIV-1 is a RNA virus, a member of the genus Lentivus within the 
family Retroviridae. Its association with Acquired Immunodeficiency Syndrome was 
discovered 30 years back, though its existence was found out to be around 1920-30(1), there is 
no treatment available to eradicate the disease till now. Total of 35.3 million people are living 
with HIV worldwide. The estimated number of people newly infected with HIV is 2.1 million 
in the year 2012. The number of AIDS related deaths totally is about 1.5 million according to 
2013 WHO statistics(2). In the last one decade India has shown very good progress in the 
control of HIV infection with a reduction in the HIV infected individuals  of  about 4 lakhs in 
a deacde and a 57 % reduction in the new cases during the same period i.e 2000-2011 (3) . It is 
mainly transmitted through three major routes; sexual, parenteral and mother to child(4). The 
virus infects the CD4+ T lymphocytes which form an important part of adaptive immune 
response in the body. The replication of the virus within the CD4+ T cells is continuous and 
further leading to destruction of these cells leading to insufficient host immune response. This 
leads to the development of various opportunistic infections(5). Thus the progression of 
disease among  HIV infected people leads to spectrum of clinical presentations including 
Acquired Immunodeficiency Syndrome (AIDS). Antiretroviral Therapy (ART) is the only 
treatment available to control the viral replication, thereby decreasing the AIDS related 
mortality and morbidity. 
There are several host factors that can affect the susceptibility to HIV, disease progression and 
resistance in HIV infected individuals. The various host factors studied are APOBEC, TRIM5-
α, HLA and ∆32 deletion at the CCR5 gene. Few of the recently described host factors with 
significant association with progression and resistance to HIV are PARD3B, ZNRD1 and 
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PROX1.In addition; cytokines has got an important role in the modulation of the innate and 
adaptive immunity.. Various cytokines have also been found to affect the disease progression 
like IL-10, IL-21, TNFα, MIP1-α and RANTES. 
IFN-λ is a newly discovered group of antiviral cytokine. IFN-λ subfamily is comprised of 
IFN-λ1, IFN-λ2, IFN-λ3  which are also called interleukin-29 and interleukin-28A, 
interleukin-28B respectively(6). It is documented to have antiviral activity in various viral 
infections(7).The antiviral activity on HIV is documented in few studies in vitro, which have 
reported that IFN-λ could inhibit the HIV replication. 
Four landmark studies published in 2009  described a clinical association between  the 
response to treatment with pegylated interferon and ribavirin(PEG-IFN-α) among hepatitis C 
virus (HCV) infection with IL28B polymorphism(8)(9). Both  spontaneous HCV clearance 
and a sustained viral response following PEG-IFN-α plus ribavirin therapy correlated with 
wild type genotypes of CC at rs12979860 and TT at rs8099917(9)(10). A single nucleotide 
polymorphisms (SNPs) reported  in the IL28B gene locus, that encodes the IFN-λ3 protein can 
modify this. The Role of IL-28B polymorphism in HIV infected individuals is not clear. Only 
few studies have documented its association in HIV infected individuals. 
Studies on the association of IL-28B polymorphism in HIV patients are contradicting and 
limited. Serra et al ,( 2008), showed that the CD4, CXCR4, and CCR5 protein expression  
increased when the PBMC pretreated with IFNλ-2 and is  associated with enhanced binding 
and replication of HIV-1. Hou et al ,(2009), IFN-λ enhances  the APOBEC3G and 
APOBEC3F expression at both the mRNA and protein levels in macrophage. Rallon et al 
,2011 and Sajadi et al (2011), showed that the association of the IL-28B SNP with HIV 
progression of disease or  protection agaist HIV (11)(12). 
Based on the anti-HCV properties of IFN-λ and the association of IL-28B polymorphism with 
better treatment outcome in HCV infection, in this study we looked at the association of IL-
20 
 
28B polymorphism and immune recovery among HIV-1 infected individuals following 6-9 
months of antiretroviral therapy (ART).  It is also important know the effect of these 
polymorphism and the IL-28B cytokine level both in the expression and plasma level as this 
cytokine s found to have antiviral effect. In this reported study an effort was also made in this 
direction.Based on the anti-HCV properties of IFN-λ and the association of IL-28B 
polymorphism with better treatment outcome in HCV infection, in this study we looked at its 
association in HIV infected individuals following 6-9 months of ART.  
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2. REVIEW OF LITERATURE 
                     
2.1. History of HIV 
 
The origin of the AIDS pandemic began in June 1981 when the Centers for Disease Control 
and Prevention (CDC) in the USA published a report in the Morbidity and Mortality Weekly 
Report on five cases of rare Pneumocystis carinii pneumonia in previously healthy young 
homosexual men in Los Angeles (Centers for Disease Control, 1981b). More case reports by 
Gottlieb et al (1981) and Masur et al (1981) revealed that this disease being associated with a 
depletion of T-helper cells were described(13)(14). In that same year, reports of a rare and 
aggressive form of Kaposi‘s sarcoma in young homosexual men in both New York and 
California 15 appeared(15), which were also associated with a loss of T-helper cells (Stahl et 
al ., 1982)(16). This condition was later officially named Acquired Immunodeficiency 
Syndrome, or AIDS, by the end of 1982.  
L. Montagnier and R. Gallo (Gallo and Montagnier, 2003) described their search for the 
causative agent of AIDS during the early years of the epidemic. As the cases of AIDS were 
observed to transmit through blood and sexual activity, from mother to child, as well as 
through filtered blood products containing clotting factors for haemophilia, a virus was 
thought to be the transmissible agent. The observations that the depletion of CD4+ T-helper 
cells was the biological marker in AIDS patients and AIDS-like wasting syndrome that was 
caused by lymphotropic retroviruses in animal models together led to a search for a retrovirus 
or a variant of the human leukemia virus (HTLV) as the causative agent of AIDS. 
The association between AIDS and HIV was made by Barré -Sinoussi and Luc Montagnier at 
Pasteur Institute in May 1983.They described the isolation of a novel retrovirus from a lymph 
node of a homosexual patient with multiple lymphadenopathies(17). T lymphocytes from a 
healthy adult donor and from umbilical cord blood of newborn were used to propagate the 
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retrovirus. Viral core proteins were found to be not immunologically related to P24 and p19 
proteins of subgroup I of HTLV.  Reverse transcriptase activity was detected in the culture 
supernatant after 15 days of culturing the lymph node lymphocytes, indicating the presence of 
a retrovirus that was then observed under electron microscopy. 
 Antisera to HTLV-1 did not react with cells infected with the novel virus, indicating that the 
new virus was distinct from HTLV. A protein of similar size to the p24 core protein of 
HTLV-1 was found, but was not recognized by antibodies to the HTLV-1 p24 protein. The 
viral core proteins were not immunologically related to the p24 and p19 proteins of subgroup 
I of HTLV(17).  
Based on these observations, Barré-Sinoussi et al ,1983. concluded that the 16 novel virus 
belonged to a general family of T lymphotropic retroviruses, which was related to but distinct 
from HTLV. The virus was subsequently called lymphadenopathy virus (LAV).  
Vilmer et al ., 1984, reported the isolation of LAV from two siblings with Hemophilia B. In 
May 1984, Robert Gallo and his coworkers reported the isolation of a novel retrovirus from 
individuals with AIDS and subsequent studies showed the evidence of this retrovirus being 
the etiological agent for AIDS(18). Serological analysis of antigens of HTLV-III, detected 
specifically by antibodies in serum from AIDS or pre-AIDS patients by Western blot 
technique, revealed that they are similar in size to those found in other HTLV subgroups. 
Hence concluded that HTLV-III is a member of HTLV family(19). The virus was called 
human T-lymphotropic virus type III, or HTLV-III.  
In August 1984, Jay Levy (Levy et al, 1984) reported an isolation of retroviruses from 
patients with AIDS and called it as AIDS-associated retrovirus, or ARV which had a type-D 
morphology, Mg
2+
 dependent reverse transcriptase and cytopathic effect on lymphocytes. 
They cross reacted with antiserum to LAV isolated from AIDS patients in France(20).  
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In 1985, molecular cloning and sequencing techniques showed that LAV, HTLV-3 and ARV 
are same species(21). The International committee on the taxonomy of the virus 
recommended that the terms LAV, HTLV-III and ARV should not be used and named it as 
Human Immunodeficiency Virus (HIV)(22). 
2.2. GLOBAL BURDEN 
 Total of 35.3 million (33.1-37.2 million) people are living with HIV worldwide, of which 
adults are about 31.8million, women about 16.0 million and children(<15 years) about 3.2 
million. The estimated number of people newly infected with HIV is 2.1 million (1.9-2.4 
million) of which adults are about 1.9 million and children (<15 years) 240,000.The number 
of AIDS related deaths  totally is about 1.5 million(1.4- 1.7million) with adults of about 1.3 
million and children (<15 years) of about 190,000 according to 2013 WHO statistics. The 
worldwide prevalence of HIV among adults is as shown in the figure 1 below(2).  
 
Figure: Global prevalence of HIV in different WHO regions (Source: WHO 2013). 
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2.3. INDIAN SCENARIO 
The NACO annual report 2012 on Indian scenario revealed that there is an overall reduction 
of 57% in the newly infected adults, i.e from 2.74 lakhs in the year 2000 to 1.16 lakhs in the 
year 2011 in India. The adult HIV prevalence has decreased from 0.41% (2001) to 0.27% 
(2011). The number of people living with HIV is estimated to be decreased from 24.1 lakh in 
2000 to 20.9 lakhs in 2011 according to NACO Annual report 2012-13(4). Eighty three 
percent of these infections occur in adults in the age group of 15-49 years.  
A total of 6.04 lakh individuals living with HIV are receiving ART as of 2012-2013 National 
AIDS Control Organization (NACO) statistics. The high risk group of population includes 
female commercial sex workers, intravenous injection drug users, men having sex with men 
and transgenders. The prevalence is twenty times higher in risk groups. Heterosexual 
contributes to 87.4% of the infections and homosexual route contributes to 1.3%(4) . The 
infection is transmitted from the high risk group to the general population through the bridge 
population which includes the truck drivers and the migrant population (clients of sex 
workers). Married women are at risk of acquiring infection from their husbands who mostly 
get infected because of their promiscuous behavior(23). Studies have shown that 
serodiscordant couples are at risk of contracting the infection influenced by various 
behavioral patterns and socio-economic factors. Approximately 5.4% of the infections are 
due to transfer from mother to child and 1% due to parenteral transmission through blood and 
blood products (2). Needle sharing for intravenous drug abuse is the predominant mode in 
North Eastern states of India accounting to 1.6% of infections. (3).  
The distribution across the states within the country is heterogeneous as shown in figure 2 
below and the highest prevalence (1.4%) is noted in the north eastern states.  
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Figure 2: District-wise adult HIV prevalence in India in different states  (Source: NACO Fact sheet 2013-
14) 
 
Tamil Nadu is one among the high risk states with the prevalence of 0.33%, it being higher 
than the national prevalence (24). The National AIDS Control Programme (NACP I-III) was 
introduced in India in the year 1992 for implementation of policies to combat the problem of 
HIV. NACP IV over 2012-17 aims to accelerate the process of reversal, further strengthening 
the epidemic response in India through a cautious and well-defined integration process.  Main 
objective of NACP IV is to reduce new infections and provide comprehensive care and 
support to all PLHIV and treatment services to all those who require it. The introduction of 
targeted interventions and ART has changed the trend of HIV in India. The prevalence has 
reduced from 0.39% in 2004 to 0.27% in 2011. There are 380 ART centres and around 10000 
Integrated Counseling and Testing Centres (ICTC) in India. These government funded 
centres provide pre and post test counseling, promote safe sexual practices and offer Highly 
Active Antiretroviral Therapy (HAART). There was a 29% reduction in the deaths due to 
AIDS in the five year period from 2007-2011(4). Also the rate of new infections among the 
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high risk group has stabilized as a result of awareness and education. Newer policies and 
strengthening of the existing programmes has made it possible to cause these changes. 
 
2.4. DIVERSITY AND ORIGIN OF HIV 
2.4.1. Source of HIV infection 
 
The source of  HIV-1 and HIV-2 infection to humans was postulated to be by several cross 
species transmissions of simian immunodeficiency viruses(SIVs) from chimpanzees(SIVcpz) 
and sooty mangabeys (SIVsm) respectively (25).It is also shown that SIVcpz can cause 
AIDS-like immunopathology in chimpanzees as SIVs were considered as non-pathogenic in 
their hosts (26).Later it was confirmed that HIV-1 was derived from SIVcpz from the Pan 
troglodytes troglodytes subspecies of chimpanzees (27). Another study showed that HIV-1 of 
group M (major or pandemic group) and N (non-major, non-outlier) arose from two distinct 
SIVcpz strains, circulating in two geographically separated chimpanzee populations present 
in west central Africa and HIV-1 of group O (outlier) as the result of a cross-species 
transmission of SIVgor in gorillas(28).  
The earliest known HIV-1 seropositive infection was detected in 1959 from a plasma sample 
from an adult male Kinshasa  from Democratic Republic of Congo(29). Phylogenetic 
analyses of HIV-1 and HIV-2 sequences have revealed that the origin of HIV-1 infection 
leading to the pandemic at present to around 1920-1930 in Central West Africa including the 
1959 sample of HIV-1 and the origin of HIV-2 is estimated to 1940 in West Africa(1)(30). 
Phylogenetically, HIV-1 can be classified into three divergent lineages arising from a 
separate transmission events from chimpanzees(31). Lineages are group M(major), N(non-
major, non-outlier) and O(outlier). In 2009, a new HIV was identified in a Cameroonian 
woman which was closely related to gorilla Simian Immunodeficiency Virus(SIVgor) distinct 
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from HIV-1 groups M, N and O and designated it as HIV-1 group P(32).Group M is seen 
worldwide and can be classified into genetic subtypes. Groups N and O are limited to few 
individuals in Central Africa(31).The M group is the most prevalent in the world among the 
three groups. It has nine subtypes (A-D, F-H, J, K), all the subtypes have originated from 
Central Africa. The amino acid distances in the env gene between the subtypes in the major 
group is about 25-35% and in the gag gene it is about 15%.Within subtypes A and F there are 
sub clusters namely A1, A2 and F1, F2 respectively. Subtypes B, C and G have genetically 
localized sub-clusters which share common ancestry, Subtype B from Thailand, subtype C 
from India, Ethiopia and Brazil  and subtype G from Spain and Portugal(33). 
Recombinant forms are seen in geographic areas where more than one type is circulating are 
reported. If two different subtypes of HIV-1 infect a single one individuals , following 
replication a mosaic genome can be resulted comprising regions from  the two subtypes. This 
is due to the ―template switching‖ ability of the reverse transcriptase enzyme.  
There are two types of recombinant forms– 
1)Circulating Recombinant Forms (CRF) and the Unique Recombinant Forms (URF)(34). 
CRFs are the recombinants identified in at least three epidemiologically unlinked individuals 
characterized by full-length genome sequencing. There are currently 66 recognized CRFs and 
one for HIV-2(35). Majority of the CRFs reported are from Africa. The formerly designated 
subtypes E and I are now reclassified as CRFs. 
2) Unique Recombinant Forms (URF) have not shown  any evidence of epidemic spread and 
are thought to arise due to secondary recombination of a CRF. These HIV-1 strains with 
unique mosaic structures have been reported in epidemiologically linked persons. Currently 
there are about 30 of them 
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HIV is the most variable of human pathogens, and it exists as a swarm of highly related but 
non-identical viral genomes known as ―quasispecies‖.  
The sources of this variation are due to these three factors:  
1) The rapid replication rate of the virus, which is estimated to produce 10
10
 virions per day 
in an infected individual(36)  
2) The high error rate of reverse transcriptase (RT) due to lack of proof reading. 
3) High recombination rate due to the alternate copying from the two RNA molecules found 
in each virion(37).  
There are two types of HIV spreading in the human population. HIV type-1 (HIV-1) is the 
cause of pandemic.HIV type-2(HIV-2) was discovered in 1985(38).HIV-2 is more commonly 
seen in West African countries like Senegal, Guinea, Guinea-Bissau and Senegal, prevalence 
being 1-10%.It is also found in countries with past socio-economical links with Portugal  
such as France, India, Angola, Mozambique and Brazil(39).  In India a dual epidemic of 
HIV-1 and HIV-2 is ongoing with HIV-1 being the predominant one. 
 
2.4.2. HIV-1 subtype C 
 
Several genotype study carried out across India had shown the high prevalence of subtype C 
varying form 65% to 97.8 %(40).    
High prevalence of subtype C is seen in India. It shares at present 50% of the global 
infections(41)(42). Subtype C demonstrates several interesting genotypic and phenotypic 
properties. Studies have shown that HIV-1 subtype C long terminal repeat (LTR) has a third 
NF-κB site whereas most non-C strains including subtype B viral strains have merely two 
NF-κB sites. Recent study in India, reported the presence of an additional 4th NF-κB in LTR, 
and four NF-κB strains are expanding and replacing the three NF-κB sites containing subtype 
C viruses. Individuals who are infected with viruses harboring four NF-κB sites had high 
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viremia compared to those individuals with virus containing only three NF-κB sites, although 
there was no significant difference in their CD4+ T-cell counts exists (43), which gave the 
conceptual premise that additional NF-κB in the HIV-1 subtype C LTR might enhance the 
viral replication competence by enhancing the infectivity. 
 
Another important difference is in neuropathogenetic ability. HIV-associated dementia 
(HAD) is common among untreated HIV-1 subtype B-infected individuals, but less common 
in subtype C infections. Apart from this, several subtype C specific genetic signature residues 
were reported clinically important reverse transcriptase (RT) and protease (PR) region of 
Pol(44). Significant co-receptor related disparities also have been observed in HIV-1 subtype 
C. In the later stage of disease nearly 50% of the subtype B strains are X4-tropic, while in 
subtype C, majority the strains use exclusively the CCR5 co-receptor (45).  
Significant disparity also has been observed in the clinical course of HIV-1 infection and 
development of drug resistance with subtype C viruses. Studies have shown that a substantial 
proportion of HIV-infected adults maintained a high viral set point after acute subtype C 
infection and might be responsible for rapid spread of this viruses (40). However, a recent 
study from East and Southern African countries showed that subtype C and non-C (A,D & 
other) subtypes do not differ significantly in terms of their viral load and rapid spread of 
subtype C (46). Thus the spread of HIV-1 subtype C strains is still inconclusive. However, 
there are likely that multiple factors including viral and host immuno-genetics as well as 
clinical and geographical disease management strategies can play a crucial role in the rapid 
spread and prevalence of HIV-1 subtype C strains globally(40). 
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2.5. HIV-1 Transmission 
HIV-1 can be transmitted along three major routes. The first route is through direct exposure 
to HIV-1 positive blood or blood products, either in donated blood or contaminated needles, 
and represents about 5-10% of HIV-1 infections worldwide.  
The second route is via mother-to-child transfer, and represents about 15% of new infections 
in (UNAIDS/WHO, 2013). The other route is through sexual contact primarily at the genital 
and rectal mucosa, and represents the vast majority of all new infections. NACO estimation 
showed 87.4% through heterosexual route and 1.3% through homosexual route(3). The 
probability of infection through sexual contact can vary greatly, and is dependent on the viral 
dose and also on whether the virus is transmitted directly into the blood via breaks in the 
epithelium or across intact mucous membranes. 
Circumcision confers a reduced risk of HIV-1 infection for men, highlighting the important 
role of the foreskin in HIV-1 transmission (Gray et al ., 2007).Various factors can lead to an 
increased risk of HIV-1 transmission, such as physical abrasion, abnormalities in the vaginal 
flora or genital ulcers caused by sexually transmitted diseases(47).Although the events on 
how HIV-1 can lead to an established infection when it reaches the epithelium is not clearly 
understood, studies on explants models have shown that HIV-1 can directly infect 
Langerhans cells, subepithelial DCs, macrophages and CD4+ T cells(48). 
The probability of HIV transmission depends on the amount of the infectious virus particles 
present in the body fluid, mainly blood and genital fluid in the index patient and the extent of 
exposure of that body fluid. Also, the susceptibility of the exposed individual is also clearly 
important. Generally, transmission events occurs among individuals with a blood viral load 
>3.5 Log10 copies/ mL. The individuals who are at risk of acquiring infection through this 
route include injection drug users (sharing of needles and syringes), those receiving blood 
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and blood products, transplanted organs. Injection drug users account for 1.6% of the 
infections in our country(3). 
 
2.6. HIV-1 Structure 
The average diameter of a mature HIV-1 virion is about 145 nm (49) and is enveloped with 
host cell-derived lipid bilayer embedded with virus-encoded Env consisting of the surface 
glycoprotein gp120 non-covalently linked to the transmembrane glycoprotein gp41(49).The 
diagrammatic representation of structure of HIV is shown in figure 3. 
 
Figure 3: Diagrammatic representation structure of HIV-1 virus (Source: Robinson et 
al ,2002) (50) 
 
 
The functional viral envelope spike exists as a trimer of gp120/gp41 on the virus surface(51). 
Structural data is available for the gp41 ectodomain in its fusogenic state, revealing a six-
helix bundle consisting of a central parallel trimeric coiled-coil of the three N-HR helices, 
surrounded by the three C-HR helices in an anti-parallel hairpin fashion (52). Formation of 
the six-helix bundle is essential for fusion of the cellular and viral membranes. The surface 
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glycoprotein gp120 consists of five conserved (C1-C5) and five variable (V1-V5) 
regions(53). The V3 region was also found to protrude from the gp120 core, which could 
explain its immunodominant properties(54). CD4 binding was also observed to be dependent 
on sequences within the C3 and C4 regions (55) 
Below the virus envelope is a layer of trimeric MA proteins which interacts with the lipid 
bilayer via amino (N)-terminal myristoyl groups. The MA shell surrounds a cone-shaped 
core, consisting of hexameric CA proteins forming a hexagonal lattice(56)(51). The conical 
core contains the nucleocapsid (NC) protein, which is closely associated with the viral 
genomic RNA. The NC protein is a small, 55 amino acid residue-protein, which contains 
zinc-finger motifs common to many proteins that bind nucleic acids (57) 
 
2.7. HIV-1 genome 
HIV has a diploid, linear, single-stranded RNA ( 9.5 kb genome) of positive polarity, which 
use a virus-encoded reverse transcriptase to convert their genomic RNA into DNA positive-
sense. The DNA is subsequently incorporated into the host genomic DNA where it resides as 
a provirus, and consists of three main open reading frames, the gag (group-specific antigen), 
pol (polymerase) and env (envelope) genes (58). Sequencing of the HIV-1 genome in 1985 
classified the virus as part of the Lentivirus genus ,whose other members include the sheep 
visna/maedi lentivirus that also cause slow disease syndromes in mammals (59). 
The gag gene encodes a 55 kDa Gag precursor polyprotein (Pr55Gag), which is cleaved by 
the viral protease into matrix (MA or p17), capsid (CA or p24), nucleocapsid (NC or p7) and 
p6 proteins, as well as the two smaller spacer peptides SP1 and SP2 . The pol gene encodes 
the viral enzymes protease (PR or p15), reverse transcriptase (RT or p66 and p51) and 
integrase (IN or p31). These enzymes are initially synthesised as part of a Gag-Pol precursor 
polyprotein (Pr160Gag-Pol), which is produced by ribosome frameshifting near the 3‘ end of 
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gag, but cleaved into individual enzymes by the viral protease(58).The env gene encodes an 
Env precursor glycoprotein(gp160), which is cleaved and processed by cellular enzymes to 
produce a non-covalent complex of a surface glycoprotein (SU or gp120) and a 
transmembrane glycoprotein (TM or gp41)(60)  
 
 
Figure 4: HIV-1 genome (source: Harrison’s principle of Internal Medicine 18th 
edition)(5)  
 
The HIV-1 genome also contains genes encoding regulatory and accessory proteins, located 
downstream of the pol gene(57). The tat and rev genes contain two exons each and encode 
the gene regulatory proteins Tat (Transactivator of transcription) and Rev (regulator of 
virion), whereas the vif, vpr vpu and nef genes encode the accessory proteins Vif (viral 
infectivity factor), Vpr (viral protein R), Vpu (viral protein U) and Nef (negative factor)(61) 
.The HIV-1 genome is flanked by two long terminal repeats (LTRs) at both the 5‘ and 3‘ end 
of the integrated provirus genome, and are 630-640 bp long(62). The LTRs consist of the U3 
region that contains the viral promoter and enhancer sequences, the R region that contains the 
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polyadenylation signal, and the transactivation response element (TAR) that serves as the 
binding site for the viral Tat protein. The diagrammatic representation of HIV-1 genome and 
its component genes are summarized in the figure 4.  
 
The secondary structure of the complete single-stranded RNA genome of HIV-1 was recently 
determined, which can function to regulate the translation and facilitate the proper folding of 
proteins with implications for viral fitness (63). 
 
 2.8. HIV-1 life cycle and replication 
Study of viral replication helps us for the better understanding of viral activity and selection 
of therapeutic strategies for the control of virus. Stages are  
2.8.1. Virus entry 
2.8.1.1 .HIV-1 Receptors 
 
Understanding of the cellular receptors for HIV-1 is crucial as the virus needs to interact with 
these receptors in order to gain entry into the host cell. Blocking of these interactions, for 
example through the use of antibodies, can potentially block virus infection of the cell. The 
cellular receptor for HIV-1 was identified to be CD4 in 1984(64), when they found that 
monoclonal antibodies (mAbs) to CD4 were able to block HIV-1 infection. The CD4 antigen 
is a transmembrane glycoprotein belonging to the immunoglobulin superfamily of receptors 
and is expressed predominantly on T helper cells but to a lesser extent on other cells types 
such as monocytes,  macrophages, dendritic cells, eosinophils and mast cells(65). CD4 on T 
helper cells acts as a coreceptor by binding to the non-polymorphic regions of MHC class II 
molecules on antigen-presenting cells and is involved in the activation of antigen-driven T 
cell responses(66). In the initiation of the HIV-1 entry process, the gp120 portion of the 
envelope spike was discovered to bind to the D1 domain only(67). 
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As non-human cells engineered to express CD4 only were not susceptible to infection and 
other human components or cofactors are involved, It was realised that a coreceptor is 
required for HIV-1 entry(68). This missing coreceptor for HIV-1 entry was identified to be 
CXCR4 in 1996, where Feng et al . showed that co-expression of both CD4 and CXCR4 are 
required to render previously non-permissive cells susceptible to infection (69). However, 
this was found to support the infection of T cell line-tropic isolates of HIV-1 and not with 
macrophage-tropic strains and primary T-cell tropic strains, indicating that yet another co-
factor was responsible for mediating entry for the latter isolates.  
The coreceptor for macrophage-tropic HIV-1 was identified by several groups to be CCR5, 
which is also the receptor for various chemokines such as RANTES, MIP-1ɑ and MIP-
1β(70). Other coreceptors, such as CCR2 and CCR3, can also mediate entry of some HIV-1 
strains.The gp120 portion of the envelope spike was found to bind to the first and third 
extracellular domains of CCR5 and CXCR4 (54). All primary HIV-1 isolates use one or both 
of CCR5 and CXCR4 as co-receptor.  
Virus isolates are now classified based on coreceptor usage, and are referred to as CCR5- or 
CXCR4-using viruses, or R5 and X4 viruses, or R5X4 for dualtropic viruses(71). CCR5 
using viruses were observed to be preferentially transmitted over CXCR4 using viruses 
although CXCR4 using viruses have been associated with lower CD4+ T cell counts and 
faster progression to AIDS(72). 
 
The HIV-1 entry process is initiated by attachment of the gp120 subunit of the viral envelope 
spike to the primary cellular receptor CD4(64). Binding of gp120 to CD4 triggers a series of 
conformational rearrangements in gp120 and in the envelope spike leading to the formation 
of a pre-hairpin intermediate which later springs out to insert the gp41 fusion peptide into the 
host cell membrane. This results in the exposure of the coreceptor binding site, thus allowing 
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either of the main cellular co-receptors CCR5 or CXCR4 to bind to gp120. The fusion of 
viral and cellular membranes coincides with formation of six-helix bundle(52). The V3 loop, 
in particular the amount of net positive charges on the V3 loop, is the main determinant for 
co-receptor usage and thereby cell tropism , although sequence changes in the V1, V2, C3 
and C4 regions of gp120 and in gp41 have been implicated(54)(73). 
Virus entry can also take place through cell-cell transfer via a virological synapse  and are all 
dependent on HIV-1 envelope glycoprotein and CD4. Such cell-cell spread of virus and its 
ability to evade antibody responses remain unclear. Although the virus is generally thought to 
enter a cell through fusion with the plasma membrane, the virus has also been observed to 
enter via endocytosis in a pH-independent step(74). 
 
2.8.2. Uncoating and Reverse transcription 
 
After virus entry, the process of viral core uncoating which is unclear and formation of a 
reverse transcription complex (RTC) occurs. Uncoating involves the disassembly of CA and 
release of the viral ribonucleoprotein complex. This process remains to be elucidated but has 
been suggested to involve both viral and cellular factors (75), in particular the cellular protein 
cyclophilin A(57). The cellular tripartite motif protein TRIM5ɑ can associate with the CA 
and promote its degradation, leading to accelerated core disassembly and uncoating, and thus 
restrict retroviral infection in a species-specific manner (Stremlau et al ., 2004;Stremlau et al , 
2006).  
The various TRIM proteins associated with inhibition of HIV-1 replication is summarized in 
table 1 below.  
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Table 1: Summary of TRIM proteins involved inhibition of HIV-1 replication. 
Protein Organism Virus 
target 
Replication 
step 
Site Ref 
TRIM-5ɑ African green 
monkey, macaque 
CA Pre-RT Cytoplasm (76) 
TRIM-5-
CypA 
Owl monkey CA Pre-RT Cytoplasm (77) 
TRIM-19 Humans ? Trafficking Cytoplasm (78) 
TRIM-22 Humans ? Transcription Nucleus (79) 
TRIM-32 Humans Tat ? Nucleus (80) 
 
The RTCs are large nucleoprotein structures consisting of packed filaments containing IN 
and Vpr and interacts with the cytoskeleton(81). Reverse transcription of the viral genomic 
RNA into a double-stranded DNA genome is thought to take place essentially within the RTC 
by the viral RT, which possess both DNA polymerase and RNase H activities to degrade the 
genomic RNA template(82). The RT polymerase lacks any proof-reading ability and is 
therefore highly error-prone, making approximately 3.4 × 10
5
 errors per base pair per cycle to 
cause the extreme sequence variation observed among HIV-1 isolates. In addition, RT binds 
with low affinity to its template and can hence make frequent jumps between the two RNA 
genomic molecules. If the two genomic RNA molecules are different, this ability results in 
the generation of genetically recombinant DNA genomes, thus contributing to genetic 
variability(83). 
The reverse transcription process can be inhibited by a cellular cytidine deaminase protein 
called APOBEC3G, and thus restrict retroviral replication by deaminating cytosine residues 
to uridine. This causes gaunosine to adenosine hypermutation in the opposite strand hence 
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inactivates the viral replication. Sheehy et al  described in HIV-1, the restriction overcome by 
the viral virion infectivity factor (Vif) protein, which mediates polyubiquitylation and 
proteasomal degradation of APOBEC3G, thus preventing APOBEC3G incorporation into 
virions and its modulation of the reverse transcription process(84). 
 
2.8.3. Integration and transcription 
 
HIV-1 replication requires that the virus enters the nucleus. Once the reverse transcription is 
complete, the RTCs are gradually transformed into pre-integration complexes (PICs) in a 
process that is little understood. The PICs contain the viral genomic DNA and viral protein 
IN, and are actively imported into the nucleus with the help of importin 7 (81), and the viral 
protein Vpr which contains nuclear localisation signals .Once the pre-integration complex has 
been imported into the nucleus, the viral DNA is integrated into the cellular genomic DNA 
and resides as a provirus in the host genome. This is solely mediated by viral IN and shown 
to specifically integrate into transcriptionally active regions of the host genome(85). Once 
integrated into the host genome, the provirus can stay latent or be transcribed by the cellular 
machinery. Prior to the production of the viral transactivator Tat, the HIV-1 promotor on the 
5‘LTR is activated by cellular transcription factors alone, resulting in low transcriptional 
levels and short transcripts. Once Tat is produced, it strongly enhances transcriptional 
activation and elongation in a positive feedback loop (86). 
After transcription, the viral RNAs are polyadenylated, spliced and exported from the 
nucleus. The obtained transcripts are either unspliced (9 kb), incompletely spliced (around 4 
kb), or fully spliced RNAs (around 2 kb). The primary HIV-1 RNA transcript or unspliced 
RNAs are used for expression of Gag and Gag-Pol precursors or packaged into virions as 
genomic RNA. Incompletely spliced mRNAs have the gag-pol region spliced out and can be 
used for expression of Env, Vif, Vpr and Vpu, whereas fully spliced mRNAs have the gag, 
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pol and most of env removed, contain no intron sequences, and are used to express Tat, Rev 
and Nef. The viral Rev protein promotes the nuclear export of unspliced and incompletely 
spliced viral RNAs by binding to a highly structured RNA region called the Rev responsive 
element (RRE). 
 
2.8.4. Synthesis, assembly, and processing of viral proteins 
 
 
The Gag (Pr55Gag) and Gag-Pol (Pr160Gag-Pol) polyproteins are synthesized on 
polyribosomes in the cytoplasm, and are important for membrane targeting and binding, 
multimerisation of Gag, encapsidation of viral genomic RNA and association with viral 
envelope glycoproteins anchored to the plasma membrane for 
particle budding and release (58). The MA protein is important for membrane targeting and 
binding(56). Gag multimerization is mediated by the viral NC protein at the plasma 
membrane and a layer of Gag-particles associated with the inner layer of the plasma 
membrane that will eventually form a spherical immature virus particle, with the 
encapsidation of viral genomic RNA by NC(82). 
The HIV-1 envelope glycoprotein, gp160, is first synthesized as a precursor polyprotein on 
the rough endoplasmatic reticulum (ER) where it undergoes glycosylation, folding and 
oligomerisation(86) which are made up of asparagine-X-serine/threonine motifs where X is 
any amino acid except proline. Proper folding of gp160 is mediated by the isomerisation of 
disulphide bonds and the signal peptide then cleaved. The gp160 also undergoes 
oligomerisation before exiting the ER and into the Golgi. Although dimers and tetramers 
have been observed, the functional spike exists as a trimer (67)(51)(86). To prevent the 
premature interaction of gp160 with CD4 in the ER, the viral protein Vpu has been shown to 
mediate CD4 degradation through ubiquitin-mediated proteolysis. CD4 cell-surface 
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expression is also down-regulated by the viral protein Nef, which mediates internalization 
and degradation of CD4 via clathrin-coated pits and lysosomes (87).The oligomeric gp160 is 
then transferred from the ER to the Golgi, where the newly added N-linked high-mannose 
glycans are modified by mannosidase enzymes, initiating the formation of complex N-linked 
carbohydrate glycans. The variability in glycosylation and processing of glycans contributes 
to the heterogeneity of the HIV-1 envelope. The trimeric gp160 then undergoes 
endoproteolytic cleavage in the Golgi to form the surface glycoprotein gp120 and the 
transmembrane glycoprotein gp41 by cellular serine proteinases. Cleavage occurs at a highly 
conserved lysine/arginine-X-lysine/arginine-arginine motif, After cleavage, gp120 and gp41 
associate non-covalently with each other(88).The envelope spikes are then directed to the 
plasma membrane through the secretory pathway and incorporated into virions(58).  
 
2.8.5. Assembly and budding of virions 
Virus assembly and budding is generally believed to occur at the plasma membrane of 
infected cells. In macrophages, HIV-1 assembly occurs in late endosomes or intracellular 
multivesicular bodies. In T cells HIV-1  buds at the plasma membrane(89).The viral protein 
p6 is crucial for the release of virus particles, as the deletion of p6 has been shown to cause 
accumulation of assembled virus particles tethered to the plasma membrane . A recently 
described protein, tetherin, was found to tether virus particles to the cell surface, but was 
antagonised by the presence of the viral Vpu protein which was previously known to enhance 
virus release(90). 
HIV-1 buds from the membrane of infected cells in an immature, non-infectious form .Upon 
budding, the viral PR is activated and cleaves the Gag precursor Pr55Gag in a stepwise 
fashion into the MA, CA, NC and p6 proteins.PR also cleaves the Gag-Pol polyprotein 
Pr160Gag-Pol, generating PR, RT and IN. Cleavage of the Gag and Gag-Pol polyproteins 
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leads to structural rearrangement of the individual Gag proteins and the formation of a 
mature, infectious HIV-1 virion containing the characteristic conical core(58). 
The stages of replication of HIV-1 virus and the proteins affecting replication is summarized 
in figure 5. 
 
Figure 5: Stages of HIV-1 replication and the cellular factors that promote or inhibit the  
HIV-1 replication (Source: Stevenson et al ,2003) (91) 
 
2.9. HIV-1 pathogenesis 
 
 
The pathogenesis of HIV-1 is complex and multifactorial involving the interplay between 
multiple viral and host factors. The direct interaction between the viral envelope and its 
cellular receptor, CD4 along with either C-C chemokine receptor type 5 (CCR5) or C-X-C 
chemokine receptor type 4 (CXCR4), results in a scenario where the virus infects key cells of 
the adaptive immune response, and hijacks the host immune system. Following infection, a 
variety of intracellular mechanisms involving the host immunological factors and viral 
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regulatory and accessory proteins are important for the clinical course of disease progression. 
A significant disparity is observed in the disease course of HIV-infected individuals. While, 
those who succumb to AIDS relatively soon after infection are termed as rapid progressors 
and there are others, termed as long-term non-progressors who manage to evade clinical 
progression without therapy even after 20-25 years (5). Even more interesting, a group of 
patients named elite controllers can control the viremia below 50 copies/ml viral load without 
any signs of immunodeficiency.  
 
2.9.1. Immune response in HIV infection 
2.9.1.1. Innate and Humoral immunity 
Mannose Binding Lectins and complement, are important soluble anti-HIV innate immune 
factors as they can inactivate virus. The effects of Tat is inhibited by anti-Tat IgM antibodies, 
and antileukocyte autoantibodies (IgM) could prevent HIV entry into cells(92). 
Neutralizing antibodies against the HIV envelope gp120 and gp41 are one of the important 
adaptive immune responses. Antibodies to cell surface proteins like Lymphocyte Functional 
Associated molecule, Intracellular cell adhesion molecule (ICAM), human leukocyte antigen 
(HLA) can also mediate these antibodies. Antibodies that attach to virus-infected cells (via 
gp120 or gp41) mediate direct killing of infected cells through antibody-directed cellular 
cytotoxicity (ADCC) in which Fc-receptor of NK cell plays a primary role(92). 
 
2.9.1.2. CELLULAR IMMUNITY 
2.9.1.2.1. T-cell immunity in HIV 
During the first weeks of infection, initial HIV-1–specific CD8+ T cell responses are 
induced. HIV-1 permanently escapes recognition by CD8+ T cell responses in the host due to 
continuous recombination and mutations in HIV-1(93). This plays a crucial role in the acute 
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phase of HIV-1 infection where the virus is not diversified yet. In the chronic phrase of 
infection the virus is more diversified.  
 
2.9.1.2.2. CD4 T cell response 
CD4+ T cell response in acute HIV-1 infection plays a crucial role in control of viral 
replication, and viral escape from CD4+ T cell–targeted epitopes. It is unclear whether the 
presence of HIV-1–specific CD4+ T cells is the cause of low viremia(94). 
 
 
During primary HIV-1 infection, there is a massive infection of both resting and activated 
CD4+ T cells in gut-associated lymphoid tissue. This leads to destruction of up to 60% of 
these cells in the early days after infection. During primary HIV-1 infection HIV-1–specific 
CD4+ T cell responses  is either  simultaneously or earlier than CD8+ T cell responses. (95). 
The role of other CD4+ T cell subsets and their role in the control of HIV-1 replication are 
also controversial. T helper 17 (Th17) cells causes immune activation, which has no 
beneficial effect in HIV-1 infection. Similarly, the role of HIV-1–specific Th2 or T follicular 
helper cell responses, which provide important helper signals for the maturation and antibody 
generation of B and plasma cells(93). 
CD4+ T cells have a major role in helping the immune response of B cells and other T cells 
through cytokines. Some CD4+ cells exhibit cytotoxic activity. CD4+ T-cell support is 
particularly important for the efficient function of CD8+ T-cell immunity.T-cell coproduction 
of IL-2 and IFN-γ appears to be beneficial for anti-HIV immunity. The CD4+ T-cells and 
dendritic cells interaction plays an important role in HIV replication and production of 
specific cytokines as we. Strong HIV specific CD4+ cell responses alone and particularly in 
association with HIV-specific CD8+ T-cells provide a good prognosis for the clinical 
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course(97). The mechanisms of CD4+ T-cell destruction are summarized in the table 2 
below. 
Table 2: Mechanisms of CD4 T cell destruction (5)(96) 
                         Direct                    Indirect 
 Loss of plasma membrane integrity 
due to viral budding 
 Aberrant intracellular signaling events 
(Antibody Dependent Cell-Mediated 
Cytotoxicity) 
 Accumulation of unintegrated viral 
DNA 
 Autoimmunity 
 Interference with cellular RNA 
processing 
 Bystander killing of viral gp120–
coated cells(Nef medicated FasL 
activation) 
 Intracellular gp120-CD4 autofusion 
events 
 Apoptosis(tat protein mediated 
caspase-8 upregulation) 
 Syncytia formation(cyclin-dependent 
kinase-1 pathway) 
 Inhibition of lymphopoiesis 
 Vpr-induced G2 arrest and apoptosis  Activation-induced cell death(Bcl-2 
and TNF) 
 Envelope mediated apoptosis  Elimination of HIV-infected cells by 
cytotoxic T cells and NK cells 
 
2.9.1.2.3. CD8+ T cell 
 
CD8+ T-cells can function in both the innate and adaptive immune systems. The CD8+ cell 
antiviral factor (CAF), blocks HIV-1 transcription by not causing any destruction of the 
infected cell. CNAR/CAF appears to be an innate immune activity that differs therefore from 
the conventional adaptive cytotoxic CD8+ CTL antiviral response that kills HIV-infected 
cells expressing specific viral epitopes. CNAR is found highest in long-term survivors (LTS); 
when this activity decreases, virus replication resumes with progression to disease(98).  
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CD8+ T cell responses in primary HIV-1 infection are induced better when compared to 
CD8+ T cells generated under persistent viral infection with abundance of antigen. Naive 
CD8+ T cells mature into effector  T-cells by recognizing the antigen and kills the respective 
target cells. Only a minor fraction of the effector cells develop into a memory cells.  
In chronic persistent infections CD8+ T cells are exhausted due to persistent antigen 
stimulation(99). Increased IL-10 plasma levels in chronic HIV-1 infection have been 
demonstrated and suggested to contribute to the general dysfunction of CD8+ T cell 
responses(100).  
 
2.9.1.2.3. Dendritic cells 
DCs are play an important role in immunity. DCs act as a link between the innate and 
adaptive immune responses. The co-infection with gram-negative bacteria along with HIV-1 
infection may facilitate HIV-1 spread by enhancing LPS-stimulated maturation of DC and, 
therefore, DC-mediated HIV-1 transmission to CD4+ T cells. IFN-α  inhibits the cell-to-cell 
transmission of HIV-1 between CD4+ T cells and DC-mediated HIV-1 transmission to CD4+ 
T cells(101).  
Matured DCs has got important role in the prevention of replication and spread of HIV-1. 
Capturing of the HIV-1 form the exposed mucosa is by the attachment of the virus to the 
CD4 and co-receptors which are expressed in low level in DC.  A C-type lectin  DC-SIGN 
expressed on DCs act as an adhesion molecule towards this.  HIV-1 binding to DC-SIGN on 
the DC surface triggers a signaling cascade that promotes HIV-1 replication in DCs(102). 
NK cells also have an important function in the pathogenesis of HIV and are influenced by 
the production of cytokines such as IFNs and IL-12. The interaction of NK-inhibiting 
receptors (KIRs) with HLA components prevents this activity. The enhanced expression of 
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KIRs, in the presence of HIV viremia, can suppress NK cell function. Recent study showed 
that NK KIR 3DL1 and its BW4-801 ligand are associated with better clinical outcome(103). 
 
2.9.2. Cytokines in HIV 
 
An array of interleukins has been studied in HIV patients on ART and its role in 
immunological response has been documented.  Interleukin-2 (IL-2) is produced by activated 
T-lymphocytes that have a key role in triggering immune responses. The main effect of IL-2 
is to induce the clonal expansion of T-lymphocytes after antigen recognition. The impairment 
in IL-2 production has been the first functional defect described in HIV-positive patients. 
Immune-based therapy with IL-2 when used as adjunctive therapy may further improve 
immune responses, demonstrated by an increase in CD4+ T-lymphocyte counts in recent 
clinical trials(104). IL-7 is cytokine produced by stromal cells, Bone marrow, thymus and 
lymph node and is critical for T-cell thymopoiesis.  Elevated levels of serum or plasma IL-7 
have been observed in CD4 T-cell lymphocytopenia, including HIV infection. Rajasuriar et al 
,(2012) demonstrated a significant association between IL-7Ra haplotype 2 and faster CD4 T-
cell recovery in Caucasians but there was no significant association in Africans(105). IL-10 is 
produced mainly by Th2 cells and occasionally by activated macrophages and non-
hematopoietic cells (eg, keratinocytes)and administration of IL-10 to HIV-1-positive patients 
has also been shown to decrease the number of circulating HIV-1 virions. IL-10 inhibition of 
T-cell apoptosis could actually be beneficial for HIV-1-infected individuals. IL-10-producing 
B cells are induced early in HIV-1 infection, can be HIV-1 specific, and are able to inhibit 
effective anti-HIV-1 T cell responses(100). Sailer et al , in their recent study, have shown 
that, during the early stages of HIV-1 infection, interleukin (IL)–18 might suppress HIV-1 by 
increasing the Th1 immune response and reducing CXCR4 co-receptor expression(106). 
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IL-21 is induced during acute and chronic HIV-infection and correlates with relative control 
of virus. IL -21 producing HIV specific T-cells correlate to better control of plasma viremia 
(107). 
 
2.9.3. IFN-λ 
IFN-λ is a newly discovered family with similar mechanism of Type I IFNs. IFN-λ subfamily 
comprised of three structurally related cytokines (IFN-λ1, IFN-λ2, IFN-λ3), which are also 
called interleukin-29 and interleukin-28A/B (IL-29, IL-28A, IL-28B) respectively. IFN-λ is 
highly conserved in human populations, implying strong evolutionary selection for these 
genes for protection against infections (8).  
The IFN-λ genes consists of  six exons, which are each encoded by a single exon (7).The 
IFN-λs exert their activity through receptor  made up of two subunits: IL-28Rα and IL-10Rβ 
(7).  The IL-10Rβ subunit is expressed on several cell types with highly expressed in cells of 
epithelial origin(108).  
High levels of IFNLs  are secreted during viral infection of lung and liver especially in 
airway epithelial cells by respiratory viruses. IFN-λ are induced by many cell types, including 
plasmacytoid dendritic cells (pDCs), conventional dendritic cells, peritoneal macrophages, T 
cells, B cells, eosinophils, hepatocytes, neuronal cells, and epithelial cells, after virus 
infections or after activation of TLR3, TLR4, TLR7, TLR9, stimulation of RIG-I, or 
Ku70(109). IFN-λs are induced by either IFN regulatory factor 3 (IRF3), IRF7, or NF-kB 
pathways (110).  
The IFN-λs bind as monomers to the IFN-λR (IL-28Rα), which then pairs with IL-10Rb to 
form the functional heterodimer receptor. IFN-λR signals are transmitted through the 
JAK1/TyK2, STAT1, STAT2, STAT3,STAT5, and IRF9 pathways to induce transcription of 
IFN-stimulated genes via ISGF3(110). These signals result in the induction of 2‘-
48 
 
5‘oligoadenylate synthetase, serine/threonine protein kinase (PKR), ISG56, and IFN-λ2/3. By 
comparison with IFN-αβ signals, IFN-λR induces longer lived activated(tyrosine-
phosphorylated) STAT1 and STAT2, and more strongly induces IFN responsive genes (MX-
1, ISG15, TRAIL,SOCS1). The cytoplasmic receptor RIG-I stimulation by viral RNA 
activates IFN-λ expression (111).The pathway mediated by IFN-λ is described in figure 6.  
  
Figure 6: Signaling pathway of IFN-ɑ and IFN-λ(Source: Donelly et al ,2011) (112) 
 
Baseline ISG expression is an indicator of successful IFN-α treatment of HCV.  Higher 
baseline hepatocyte ISG expression was observed in patients with chronic HCV infection and 
IFN-α nonrespnders.  The SNPs in the IFNλ3/4 and IL-28RA genes found to have an 
association with elevated basal ISG expression and treatment failure (113). Important 
antiviral ISGs are ISG15, MX1, OAS1-3, and PKR . IFN-λ blocks the replication of 
numerous viruses in vitro, including encephalomyocarditis virus, West Nile virus, vaccinia 
virus, vesicular stomatitis virus, foot and mouth disease, HSV-1, influenza A virus, HIV 
(6),HCV, and hepatitis B virus. 
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2.9.3.1. Role of IFN-λ in HCV 
 
The limit in level of IFN-λ induced in a natural HCV infection is unclear, as mechanisms are 
involved to inhibit the IFN-α/β response in infected hepatocytes. The HCV NS3/4A protease 
inhibits IRF-3 activation and cleaves the RIG-I and TLR signaling adapters IPS-1 and TRIF. 
A NS2 protein blocks activation of IFN-λ through an unknown mechanism that is distinct 
from that of NS3/4A, and the HCV NS5A protein can also inhibit IFN-α/β expression(114).. 
Furthermore, like IFN-α/β, IFN-λ is expressed in PBMC but not in the liver of chronic HCV 
patients(115). Hepatitis C virus (HCV) NS3/4A, the viral protease responsible for cleavage of 
the viral polyprotein, can also cleave the key adaptor protein MAVS also named VISA, 
Cardif, or IPS-1 which transmits signals from upstream sensor molecules RIG-I or MDA5 to 
downstream TBK-1/IKKε and IKKα/β/γ complex. HCV NS3/4A  can also cleave TRIF, key 
adaptor protein responsible for signal transmission ofTLR3 (116). This leads to blocking of 
both RIG-I- and TLR3-mediated activation of type I IFNs. HCV NS2 protein can also inhibit 
IFN-α, IFN-β, IL-29, and chemokine gene promoter activity(114). 
 
2.9.3.2. IFN-λ in HIV 
 
Studies explaining the role of IFN-λ IN HIV infected individuals are limited.  
Liu et al(2006) , showed that IFN-λ3 inhibits HIV infection of macrophages through TLR3 
and JAK-STAT pathway(117) 
Serra et al(2008) , reported the expression of the CD4, CXCR4, and CCR5 genes was 
increased when the peripheral blood mononuclear cells  were pretreated with IFNλ-2 and was 
found out that it was associated with enhanced HIV-1 binding and replication(118) 
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Hou et al(2009) , showed that IFN-λ enhances APOBEC3G and APOBEC3F expression at 
both the mRNA and protein levels in macrophage(6). RR Tian et al(2012) , showed that IFN-
λ3 inhibits the HIV integration and transcription in vitro (119). 
 
2.9.3.3. Role of IFN-λ in innate immunity and T- and B-cell modulation 
2.9.3.3.1. Macrophages 
 
 
The M0 phenotype of macrophage differentiates into M1 macrophage in response to IFN-γ. 
M1 macrophages produce high amounts of IL-12 and IL-23.It also produces low amounts of 
IL-10, IL-1, TNF-α and IL-6 leading to induction of Th1 cells.  
In the other side M2 cells are induced by IL-4 or IL-13. M2 cells do not present antigen to T 
cells and produce minimal amounts of pro-inflammatory cytokines. The induction of Th2 
cytokines and subsequent stimulation of T regulatory cells is the key function of M2 cells. 
The expression of IL-28RA on human DCs has been mostly seen on plasmacytoid DCs. They 
are potent producers of IFN-λ. 
 
2.9.4.3. Role of IFN-λ in Th1 or Th2 balance 
Virus-specific Th1 and cytotoxic T cells play a crucial role in control viral replication. On the 
other side B cells receive important growth signals from Th2 cytokines. Antigen presenting 
cells in particular dendritic cells and macrophages are the decision makers in differentiation 
of T-cell subsets into a Th1 or Th2 phenotype. IL-12 and IFN-γ are the critical for the 
differentiation of Th1 cells(120). Following the activation of Th1 cells through pathogen 
detection via pattern recognition receptors, antigen-presenting cells in particular DCs and 
macrophages secrete IL-12 in large amounts. IL-12 induces natural killer cells to produce 
further IFN-γ. The Th1 cells are induced mainly by transcription factor T-bet. 
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IL-4 and IL-2 are critical for T-helper cell (Th2) differentiation. The major transcription 
factor involved in Th2 lineage differentiation includes the IL-4-induced STAT6.This up-
regulates the expression of GATA3.The effects expression of T-bet and GATA3 are 
opposing. The effect of IFN-λ in T-cell mediation is summarized in figure. 
 
 
 
    
Figure 7:Impact of IFNλ3 SNP on cytokine profiling in viral infections(Source: Egli et 
al  2014)(121) 
 
 
It is shown that IL-28RA which are responsive to IFN-λ is expressed in purified naive and 
memory human CD4 T cells. The expression of Th2 cytokines (IL-4 and IL-13) was 
suppressed in CD4 T cells by IFNλ1. GATA3 expression is reduced by IFNλ1 treatment. 
This suggests that the IFNλ1 has suppressing action on Th1/Th2 balance(122) 
 
2.10. Host factor associated with HIV disease progression 
2.11. HLA association with disease progression 
The rate of disease progression and the different human leukocyte antigen (HLA) class I 
alleles are strongly associated, the interaction between the T cell receptor of the CD8+ T cells 
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and the HLA of the antigen-presenting cell is a key element in the overall control of HIV-1 
replication(93).The association of various HLA with the HIV disease progression is 
summarized in table 3. 
Table 3: HLA association with HIV disease progression 
         Fast progressors        Slow progressors / 
     long-term survivors 
High-risk exposed 
HIV-seronegative 
individuals 
 HLA class I 
homozygosity 
 Ancestral haplotypes 
8.1,35.1,44.2, A23 
 Supertype A2  A2 
 Supertype B7, B*08  BM27, BM51, BM57, 
BM1503 
 DR13 
 Haplotype A*01-B*08-
R3,B22,B*35-Px, DR3, 
DR11 
 Supertype DR13,  
Haplotype DRB1M13- 
QB1M06 
 
 
 
 
Other host factors associated with the disease progression are summarized in the table 4. 
Table 4: Various Cellular genes affecting HIV disease progression(123) 
            Gene          Genotype  Effect on progression 
Cell surface Coreceptors 
 CCR5 
 CCR2b 
 
+/ 32 
+/64I 
 
    Delay AIDS 
    Delay AIDS 
HLA 
 KIR/HLA 
 KIR/HLA 
 
KIR3DL1/HLA-B*57 
KIR3DS1/HLA-B Bw4-80 Ile 
 
    Delay AIDS 
    Delay AIDS 
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Cytokines 
 IL-10 
 IFN-γ 
 IL-4 
 RANTES 
 RANTES 
 MIP-1α 
 
-592A 
-179G/T 
IL-41-589T 
In 1.1C haplotype 
-403A/-28G 
- 
 
    Accelerate AIDS 
    Accelerate AIDS 
    Delay AIDS 
    Accelerate AIDS 
    Delay AIDS 
    Delay progression 
MBL 
 
APOBEC-3G 
TSG101 
TSG101 
Homozygosity-  
lower MBL levels 
186R 
HapC 
HapB 
     Accelerate AIDS;  
     enhance infection 
    Accelerate AIDS 
    Accelerate AIDS 
     Delay AIDS 
 
 
2.11. Genome wide association studies (GWAS) 
Several studies have been conducted to study the influence of host genetic factors in HIV 
infection. Genome wide association studies related to susceptibility, transmission, disease 
progression (AIDS) with HIV infection are summarized in the table 5. 
 
Table 5: Summary of GWAS conducted associated with HIV. 
Cohort Year Phenotype Most important 
association 
Validation Ethnicity Ref 
CHAVI 2007 RNA VL set-
point 
 
CD4 decline 
HCP5(rs2395029) 
-35 HLA-
C(rs9264942) 
ZNRDI(rs9261174) 
Significant, confirmed 
Significant, confirmed 
 
Confirmed 
Caucasian (124) 
ANRS 
PRIMO 
2008 Plasma HIV 
RNA in 
primary 
infection 
Cellular HIV 
DNA primary 
HCP5(rs2395029) 
 
 
HCP5(rs2395029) 
Significant, confirmed 
 
 
Significant, confirmed 
Caucasian (125) 
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infection   
GRIV 2009 Long-term non-
progression 
HCP5(rs2395029) 
C6orf48(rs9368699) 
Significant, confirmed 
 
Caucasian (126) 
Euro-
CHAVI, 
MACS 
2009 RNA VL 
setpoint 
HCP5(rs2395029) 
-35 HLA-
C(rs9264942) 
Significant, confirmed 
 
Caucasian (127) 
GRIV 2009 Rapid 
progression 
PRMT6(rs4118325) 
SOX5 (rs1522232) 
Putative 
 
Caucasian (128) 
Internation
al HIV 
controllers 
study 
2010 VL controllers >300 SNPs in MHC 
−35 HLA-C 
(rs9264942) 
HCP5 (rs2395029) 
MICA (rs4418214) 
PSORSIC3 
(rs3131018) 
Significant 
 
Significant, confirmed 
Significant, confirmed 
Significant 
Significant 
 
Caucasian 
African 
Hispanic 
(129) 
Queen 
Elizabeth 
Central 
Hospital, 
Malawi 
2010 Mother-to-
child 
transmission 
HS3ST3A1 
(rs8069770) 
Putative African 
  
(130) 
MACS 2010 Progression to 
AIDS 
PROX1 
(rs17762192) 
Confirmed Caucasian (131) 
 
DoD HIV 
NHS and 
MACS 
2010 RNAViral 
Load setpoint 
HLA-B*5703 Significant, confirmed African (132) 
GRIV,MA
CS,ACS 
2010 Long-term 
nonprogression 
(VL   
>100copies/ml) 
CXCR6 (rs2234358) Significant, confirmed Caucasian (133) 
CHAVI, 
Malawi 
2011 HIV 
acquisition 
rs1946518(IL-18) 
 
Significant African (134) 
MACS 2011 Progression of 
AIDS 1987 
PARD3B 
(rs11884476) 
Significant, confirmed Caucasian
Africa 
(135) 
Blood 
donors, 
Sanquin 
2011 in vitro HIV-1 
replication in 
DYRK1A Putative Caucasian (136) 
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Amsterdam macrophages (rs12483205) 
ACS 2011 progression to 
AIDS,or AIDS-
related death 
AGR3 (rs152363) Putative Caucasian (137) 
Thailand 2011 Nevaripine 
tolerance 
CCHCR1 
(rs1265112) 
Significant Asian 
African 
(138) 
African 
serodiscord
ant couples 
cohort 
2011 HIV 
acquisition 
Nil Not significant African (139) 
Multicenter 
Hemophilia 
Cohort 
Study 
(MHCS) 
 
2013 Resistance to 
HIV 
CCR5Δ32  
Heterozygosity 
CCR5Δ32  
Homozygosity 
Not significant Caucasian (140) 
AIDS 
Clinical 
Trials 
Group 
A5095 
2014 CXCR4 
coreceptor 
usage and HIV 
disease 
progression 
CCR5 Δ32(rs333) 
CCR5 
Δ32(rs1799987) 
SDF1-3′A 
Not significant Caucasian 
Hispanic 
African 
American 
(141) 
Malawi 2014 Nevirapine 
hyper-
sensitivity 
HLA-C*04:01 Significant African (142) 
CHAVI014 2014 Resistance to 
HIV 
HLA/KIR Not significant Caucasian (103) 
ALIVE, 
MACS, 
SFCC, 
MHCS 
2014 Host resistance 
to HIV 
acquisition   
CD4+ T cell 
depletion           
ZNRD1 
(rs3132130) 
Significant African-
American,
Caucasian 
(143) 
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2.12. IL-28B polymorphism  
In 2009, four landmark studies described a clinical association between IL28B and HCV 
RNA clearance with pegylated interferon and ribavirin combination therapy. This was 
associated with SNPs found in the IL28B gene locus, that encodes for IFN-λ3(144)(8). The 
SNP at rs12979860 SNP is associated with approximately 2-fold differences in spontaneous 
clearance and response to treatment(144). The wild genotype is associated with better 
outcomes, and heterozygous T/T genotype, showed the worse outcomes. The SNp at 
rs8099917 SNP also shown to be associated with a 2-3 fold difference in spontaneous 
clearance and response to therapy(9). The location of IL-28B genes and SNPs are depicted in 
Figure 8.   
 
 
Figure 8: Location of interferon lambda genes and the SNPs (rs12979860 & rs8099917) 
associated with IL-28B chromosome 19(Source: Ito K et al ,2014)(145) 
The polymorphisms associated with poor response to therapy are found at a higher frequency 
in African populations compared to European populations, consistent with the lower response 
rates of PEG-IFNα plus ribavirin treatment in African-Americans. Individuals harboring the 
rs8099917 minor allele were found to have reduced IFN-λ3 expression levels in PBMC, 
indicating that this variant may be located within a transcriptional regulatory element (8). 
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Because IFN-α upregulates IFN-λ expression, IFN-λ may amplify interferon-stimulated gene 
expression following administration of PEG-IFN-α in HCV infected individuals. As other 
host factors have also been associated with therapy outcome, the interplay between these 
various factors needs to be better defined. For example, patients who fail to achieve a 
sustained viral response after PEG-IFN-α therapy have a high pre-therapy level of 
intrahepatic ISG expression(146). 
 
2.12.1. Mechanism of IL28B polymorphism in HCV 
 
 
Langhans et al  described the suppression of IL29 levels in patients with chronic HCV 
infection(147). The unfavorable rs12979860 genotype was associated with suppressed serum 
levels of IL29 and IL28A/B and this suppression appeared to be caused by HCV E2 and NS3 
proteins(147).This indicates that IL29 levels are suppressed in chronic HCV infection, 
especially in patients with IL28B genotypes associated with poor response to treatment. 
Hence the lack of IFN-λ may present is responsible for non response. IFN-λ can directly 
inhibit HCV replication in vitro via signalling through the JAK-STAT 
pathway(115).Furthermore, liver and peripheral blood mononuclear cells (PBMCs) from 
patients with chronic HCV infection seem to express more IL28A/B RNA than do healthy 
controls(148). 
IL28B rs8099917 has been associated with differences in IL28B expression with the 
protective allele leading to an increase in messenger RNA (mRNA) expression in healthy 
individuals(8). Langhans et al  also reported higher IL29 levels in patients with the 
rs12979860 protective genotype as compared to the nonprotective genotypes . In contrast, 
Abe et al  reported low IL28B levels in liver samples of patients with the rs8099917 
protective genotype . In general, IFN-stimulated gene (ISG) induction was reported to below 
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in rs8099917 and rs12979860 protective genotypes(149). The presence of an active HCV 
RdRp in the cytoplasm generates signals to stimulate IL28B expression and that transcription 
at the IL28B promoter is influenced by the alleles present at rs28416813 which is in close 
proximity with IL28B gene(150).  
 
2.12.2. IL28B Polymorphism in HIV 
 
Studies describing the effects of IFN-λ on susceptibility of HIV-1 infection, replication and 
its association with ART are limited. 
Study by Sajadi et al , 2011 a cohort study in HIV-1 Natural Viral Suppressors(NVS) 
concluded that IL28B CC genotype does not account for the noted HIV control in NVS 
cohort. 
Martin et al  (2010) showed that IL28B rs12979860 does not influence the susceptibility to 
HBV or HIV infection or the progression of HIV infection(151). 
Rallon et al (2011)  examined the protective role of IL28B polymorphisms in 29 seronegative 
individuals at risk for HIV-infection and in 68 HIV-positive carriers with and without rapid 
progression of immunodeficiency. No protective role of IL28B polymorphism was found 
examining both HIV-disease progression and HIV-protection(11).  
Interestingly, HTLV-1 infected individuals with the CT/TT allelic variants at the IL28B 
rs12979860 gene exhibited approximately a 3-fold increased risk of HAM/TSP and had 
nearly 10-fold higher median HTLV-1 proviral loads (PvLs) than CC carriers(152) 
Kamihira et al . reported that the frequency of the rs8099917, located 3 kb upstream the 
IL28B/IFN-λ3 gene had no significant association with susceptibility to HTLV-1 infection or 
the development of Adult T-cell Leukemia in the Japanese subjects(153). 
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2.12.3. Impact of IL28B genotype on IFNλ3 secretion 
The C/C genotype leads to higher levels of IFNλ3 secretion in HCV infected patients. In 
addition to its anti-viral activity, IFNλ3 exerts potent immunomodulatory effects allogeneic 
stem-cell transplantation patients carrying the T/T genotype produce less IFNλ3(154), which 
in turn results in lower levels of circulating Tregs, leading to a more efﬁcient expansion of 
CMV-speciﬁc T cells, which are critically involved in controlling CMV replication in either 
the presence or absence of antiviral therapy, the impact of the donor IL28B SNP genotype 
would be more pronounced than that of the recipient provided that IFNλ3 is mostly produced 
in response to deﬁned stimuli by macrophages and pDCs, which are of donor origin(110). 
If there is any association of CC or TT genotype with HIV susceptibility and progression that 
can be used as a prognostic marker in HIV-1 infected individuals 
 
2.12.4. Activation of IFN-λ  
 A series of SNPs of IFNL3 and IFNL4 genes have been discovered and that impact the 
binding of transcription factors and methylation sites.  This affects the the promoter 
output.(144)(113).  
 
Reduced IFNλ3 expression during chronic HCV infection in liver biopsies, serum and 
PBMCs were reported with  SNPs rs12979860 and rs8099917 (146). SNPs in rs12979860 
were also associated with lower IFNλ3 gene expression in CMV infected fibroblasts and 
stimulated PBMCs (155).Data on the role of IFNLs and host response to virus are widely 
available with HCV infection that has been classically treated with (pegylated) IFN-α. This 
lead to a robust antiviral immune response in patients with chronic HCV infection.  There is 
a difference in the expression kinetics between different IFNL family members during 
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stimulation of fibroblasts and human peripheral blood mononuclear cells (PBMCs)(155).  
IFNλ3 shows a peak at 24-h after stimulation with CMV, while IFNλ1 peaked by 6 hours by 
measuring mRNA levels(155). The effect of IL-28B polymorphism on IL-28B expression is 
summarized in table 6. 
Table 6: Impact of IL28B polymorphism on IL28B expression reported among different 
viral infections 
Gene SNP Genotypes Impact on 
expression 
(minor allele) 
Impact on virus 
replication and 
immunity(minor allele) 
Ref 
IFNλ3* rs12979860 Major: C/C 
Minor: 
C/T,T/T 
Reducing IFNλ3 HCV: lower rates of 
spontaneous clearance 
Acute CMV: reduced 
replication 
(113) 
(156) 
IFNλ3* rs8099917 Major: T/T 
Minor: 
T/G,G/G 
Reducing IFNλ3 HCV: lower rates of 
spontaneous clearance 
Acute CMV: high ISG 
production  and reduced 
replication  
less priming of CMV-
specific T cells 
(113) 
(156) 
* Originally these SNPs were assigned to or close to IFNL3,recent studies show that true 
location is IFNL4 for rs12979860 and between IFNL4 and IFNL4P1 for rs8099917(157) 
 
 The C allele of IFNL3 is found to have better inhibition of the the initial replication of a 
virus.  This is due to the long lasting anti-viral effect of induced ISGs. This will lead to the 
control or the clearance of the virus. Compared to this among the individuals with minor 
allele thee is low level of IFNL3 and reduced  anti-viral and modulatory ISG induction.   The 
limited IFN-α response lead to a high, short-lived ISG expression further causing  replication 
of viruses and subsequent selection of quasi-species resistant to ISGs. The constant viral 
replication in with low IFNL3 mediated regulatory activity enhances the IFN-α-mediated ISG 
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expression.  The impact on IFN-λ production in viral infection by major and minor genotypes 
is summarized in figure 9.   
 
Figure 9: Summary of  ILNλ3 SNP and impact on virus replication(Source: Egli et al  
2014)(121). 
 
Kamihira et al .2012 (153)showed that found a strange phenomenon that the IL- 28B mRNA 
expression levels in peripheral blood were lower in samples with HTLV-1/HCV co-infection 
than in samples with either HTLV-1 or HCV alone, especially significantly for HTLV-1 
mono-infection. In particular, samples carrying TT homozygotes were strongly 
downregulated, more than the minor TG hetero- and GG homozygotes.  
 
2.12.5. IFN feedback 
 The rs12979860 and rs8099917  SNPs  in the IFNL3 gene region were associated with lower 
IFNλ3 expression levels and higher baseline ISG expression(144) .There is higher ISG 
expression in IFNλ3 SNPs in spite of lower IFNλ3 gene expression which can be due to  
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(i) A disruption in the regulatory aspects (at ligand or receptors) of type-I and -III IFN 
signaling cascades  
 (ii) Significantly  lower  IFNλ3, anti-viral and modulatory ISG induction observed among  
T/G allele IFNλ3 SNP.  
 
2.12.6. Studies conducted in India 
 
A study by Sivaprasad et al  studied the distribution of genotype and allelic frequency of IL-
28B gene polymorphism in healthy uninfected controls in Andhra Pradesh, India and it was 
found that the frequency (59%) of CC genotype (wild) is significantly higher than CT or TT 
in south Indian population. 
Studies on association of IL-28B polymorphism with HCV and PEG-INFα/RBV treatment in 
Indian population are limited. 
Chinnaswamy et al , showed that SNPs like rs12979860 and rs8099917 identified by GWA 
studies are in high Linkage Disequilibrium with rs28416813 and exert their effect on the 
phenotype through rs28416813.Strong linkage disequilibrium between rs28416813 and 
another important SNP rs12979860 in two ethnic populations was reported. Hence this study 
demonstrated that the SNPs at the IL28B locus influence spontaneous clearance and 
treatment response in chronic HCV infections(150). 
Firdaus et al , concluded that CC, TT the two favourable markers at SNPs rs12979860 and 
rs8099917 are strongly associated with sustained virological response in genotype 3 infected 
population(10). 
Gupta et al , concluded that the IL28B CT/TT genotype is strongly associated  with the 
treatment non-response in patients infected with HCV genotype 3 and CC genotype of IL28B 
is associated with higher  quick viral response (158). 
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Hence, IFNλ3/4 gene polymorphism and IL28RA and its modulation of IFNλ3 expression 
have an effect on Th1 and Th2 cytokine production and memory formation during viral 
infections. Hence more studies to be conducted for the better understanding and treatment 
interventions. 
 
3. Clinical Stages in HIV infection 
The infection and clinical progression of HIV-1 is generally divided into three phases:  
a) Primary or acute infection 
The first phase of HIV-1 infection is termed as primary infection and occurs a few weeks 
after infection. During this phase, a high viremia (acute phase viremia) due to active 
replication of virus is seen and the patient is highly infectious during this phase. The 
symptoms are generally non-specific and hence frequently not recognized as signs of HIV 
infection.  
Due to the strong host immune defense during acute phase, there is a drop in viremia termed 
―set point‖. The risk of viral transmission between hosts largely depends on the viral set 
point(159). This phase is termed as latent phase since there are new or only minor clinical 
symptoms and typically varies between 5 to 15 years.  
 
b) Assymptomatic phase 
Following  6 months of acute infection phase, majority of the individuals become 
asymptomatic and usually the viral set  point  will be  <20,000 RNA copies/ml. This is a 
reflection of the host  antiviral responses  by the innate and adaptive immune systems. 
Neutralizing antibodies, NK cell and HIV specific T cell activity also leads to the reduction in 
the HIV activity.  In certain individuals even the viral load become undetectable they are 
called ‗elite controllers‘(160). HIV replication during the subsequent persistent infection 
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period can take place at low levels in the lymph nodes and other tissues and appears to reflect 
the extent of control by antiviral immune responses.  In average most of the treatment naïve 
individuals after 10 years of asymptomatic phase start showing symptoms.  There is a loss of 
immune activities especially HIV-specific CD4+ and CD8+ T-cell activities. Viral 
destruction of lymphoid tissue mirrors this progression of HIV infection(160). 
c) AIDS 
The last phase is AIDS which is characterized by rapid loss of CD4+ T-cells and highly 
elevated viral load. Due to the destruction of the body‘s immune mechanism, AIDS-
associated opportunistic infections and malignancies are manifested during this phase(5). 
The stages of AIDS progression with the association of viral load is summarized in figure10. 
 
 
    
Figure 10:The stages of AIDS progression(Source: O‘Brien et al  2013) (159) 
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3.1. Staging of disease: 
There are two system of staging employed in HIV infection. One is the WHO staging system 
and the other is CDC staging. The most commonly used one in developing countries is WHO 
staging  is described in table 7. WHO gives the clinical staging of HIV based on clinical 
manifestations and an independent staging based on immunological criteria based on the 
CD4+ T cell counts. These criteria apply to adults above the age of 15 years(42).  
 
Table 7: WHO staging of HIV/AIDS  
WHO staging of HIV/AIDS for adults and adolescents 
Clinical stage 1 
 Asymptomatic  
 Persistent generalized lymphadenopathy (PGL) 
Clinical stage 2 
Herpes zoster  
Angular cheilitis  
Recurrent oral ulcerations  
Papular pruritic eruptions 
Seborrhoeic dermatitis  
Fungal nail infections of ﬁngers 
Clinical stage 3 
Oral candidiasis  
Oral hairy leukoplakia  
Pulmonary tuberculosis (TB) diagnosed in last two years  
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
Conditions where conﬁrmatory diagnostic testing is necessary 
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Laboratory confirmation required 
Unexplained anaemia (<8 g/dl), and or neutropenia (<500/mm3) and or  
 thrombocytopenia (<50 000/ mm3) for more than one month 
Clinical stage 4 
Conditions where a presumptive diagnosis can be made on the basis of clinical  
signs or simple investigations  
HIV wasting syndrome  
Pneumocystis pneumonia  
Chronic herpes simplex infection (orolabial, genital or anorectal of >1month 
 duration) 
Oesophageal candidiasis  
Extrapulmonary TB 
Kaposi’s sarcoma 
Central nervous system (CNS) toxoplasmosis 
HIV encephalopathy 
Conditions where conﬁrmatory diagnostic testing is necessary: 
Extrapulmonary cryptococcosis including meningitis 
Disseminated non-tuberculous mycobacteria infection  
Cryptosporidiosis  
Isosporiasis  
Visceral herpes simplex infection 
Cytomegalovirus (CMV) infection (retinitis or of an organ other than liver, spleen or 
lymph nodes)  
Any disseminated mycosis (e.g. histoplasmosis, coccidiomycosis, penicilliosis)  
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3.4. IRIS 
Immune Reconstitution Inflammatory Syndrome (IRIS) is a clinical entity described in HIV 
infected individuals following adminstation of HAART and measurable viral suppression can  
lead to acute worsening of  symptoms and signs associated with underlying opportunistic 
infections (161). There is deterioration of clinical status following ART though there is  
improved immune function. This may be due the inflammatory response against the 
infectious antigen. Immune reconstitution inflammatory syndrome usually sets in patients 
with low CD4 (usually <50cell /μl) prior to treatment.   Usually this sets in within 6 weeks of 
ART.  One of the reason for IRIS may be the polymorphisms of gene encoding IL-6, IL-12, 
and TNF-α. Tadokera et al , 2013 has shown that of IL-10 family cytokines showed an 
increase in levels of transcript for IL-10 and IL-22 in IRIS patients compared to non-IRIS 
controls(162). 
 
4. Antiretroviral Therapy 
 
The primary goal of ART is to reduce HIV associated morbidity and mortality. ART will help 
in the durable viral suppression and the treatment improves immune function and lowers risk 
of both AIDS defining and non-AIDS-defining complications and prolongs life. Additional 
benefits of ART include reduction in HIV-associated inflammation and its associated 
complications.  
 
4.1. Antiretroviral therapy in India 
As on March 2013, there are around 18.13 lakhs People Living with HIV (PLHIV) registered 
at the 400 ART Centres functioning all around the country. Currently near 6.5 lakhs are on 
first line ART. Along with this 840 Link ART Centres primarily established for dispensing 
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ARV drugs, monitoring side effects and treating minor OIs. Among this 154 LACs have been 
upgraded as LAC plus 
centres to provide Pre ART services additionally(3) 
 
 
The drug regimens available in India as per NACO 2012 guidelines is summarized in the 
table 8. 
Table 8: The ART Regimens provided to HIV infected individuals as per the NACO 
guideline (2012) 
Regimen Drugs Comments 
Regimen I Zidovudine + Lamivudine + 
Nevirapine 
Hb ≥9gm/dl, not with ATT 
Regimen I(a) Tenofovir + Lamivudine + Nevirapine Hb <9 gm/dl, not with ATT 
Regimen II Zidovudine + Lamivudine + Efavirenz Hb ≥9 gm/dl, with ATT 
Regimen II (a) Tenofovir + Lamivudine + Efavirenz Hb <9gm/dl, with ATT, Hepatitis B 
and/or Hepatitis C co-infection, 
Pregnant women 
Regimen III Zidovudine + Lamivudine+ 
Atazanavir/ Ritonavir 
Regimen I & III toxicity to both NVP 
and EFV. 
2
nd
 line regimen- TDF containing first 
line regimen if Hb ≥ 9 gm/dl 
Regimen III(a) Zidovudine + Lamivudine + 
Lopinavir /  
Ritonavir 
Regimen III with severe Atazanavir 
toxicity  
First line regimen for patients with 
HIV-2 infection with Hb ≥ 9 gm/dl 
Regimen IV Tenofovir +Lamivudine+ Atazanavir/ 
Ritonavir 
Second line regimen for on AZT/d4T 
containing regimen in the first line.  
 Patients on TDF containing first line 
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regimen who develop toxicity to both 
NVP and EFV  
Regimen IV 
(a) 
Tenofovir + Lamivudine+ 
Lopinavir/Ritonavir 
Regimen IV with severe Atazanavir 
toxicity  
1
st
  line for HIV 2 infection with Hb < 
9 gm/dl  
First line for Women exposed to sd-
NVP in the past 
Regimen V Stavudine+ Lamivudine+ Atazanavir/ 
Ritonavir 
Second line for TDF containing 
regimen in the first line if Hb < 9 
gm/dl 
Regimen V(a) Stavudine+Lamivudine+ Lopinavir/ 
Ritonavir 
Regimen V with severe Atazanavir 
toxicity 
 
 
5. HIV Vaccine 
It is been 30 years since the advent of HIV, many vaccine trials were conducted. Table 9 
shows the details of all the trails carried out. 
 
Table 9: Vaccine trials conducted for HIV-1  
 
Vaccine candidate Phase Components         Countries hosted    Ref 
Canarypox plus(RV144) 
Envelope 
  3 gag,pro, env (E)        
 plus gp120 (B, E) 
Thailand (Sanofi Pasteur) (163)  
Ad5 (HVTN 502/ Merck 
023) 
   2b gag, pol, nef (B) Dominican  Republic, Haiti, 
Jamaica, Peru, South Africa, 
(164)  
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United States 
DNA plus Ad5 
( HVTN 505) 
 
     2 gag, pol, nef (B), env 
(A, B, C) plus gag, pol 
(B), env (A, B, C) 
Kenya, Haiti, Jamaica, 
Rwanda, South Africa, 
Tanzania, Uganda, United 
States 
(165) 
Canarypox plus 
lipopeptides 
 2 gag, pol, nef, env (B) 
plus cytotoxic T-
lymphocyte epitopes (B) 
France (166) 
DNA plus protein  1 T helper epitopes from 
gag, pol, vpr,nef (B) 
Peru, United States (167) 
DNA plus peptides   1 gag (B) multiple T-cell 
epitopes(plus or minus 
IL-15 or IL-12 adjuvant 
or GM-CSF) 
Brazil, Thailand, United 
States 
(168) 
DNA–PLG plus 
envelope 
  1 gag, env (B) plus 
oligomeric gp140 (B) 
United States (169) 
Anthrax-derived 
polypeptide-HIV gag 
fusion protein 
  1 gag (B) United States (170) 
DNA plus modified 
vaccinia Ankara 
  1 gag, pol, nef, tat, env 
(C) 
United States (171) 
Modified vaccinia 
Ankara 
  1 gag, pol, nef, tat, env 
(C) 
India (172) 
Fowlpox plus modified 
vaccinia Ankara 
  1 gag, pol, nef, tat, rev, 
env (B) 
Brazil, United States (173) 
Adeno-associated virus   1 gag, pr, rt (C) Belgium, Germany, India, 
South Africa, Zambia 
 
(174) 
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Venezuelan equine 
encephalitis viral 
replicon 
  1 gag (C) Botswana, South Africa, 
United States 
(175) 
 
The Thai phase 3 (RV144) vaccine regimen, ALVAC prime/bivalent clade B/E recombinant 
gp120 boost, provided an estimated 31.2% efficacy against the acquisition of HIV-1 infection 
at 42 months after vaccination. Multiple HIV-1 vaccine efficacy studies have been 
completed, yet only one trial in Thailand resulted in partial efficacy (RV144)(176). Another 
trial in Thailand (VAX003) that used a protein component of the RV144 vaccine showed no 
efficacy. The VAX003 clinical trial, in a high-risk injection drug use cohort, containing the 
same bivalent clade B/E gp120 protein immunogen as RV144, without the ALVAC prime did 
not show protection despite higher vaccine elicited neutralizing antibodies (nAbs) compared 
to RV144(176). 
Hence alternative approach like enhancing cytokine level, modulating the T-cell immunity 
seems a better way of the control of viral replication and hence reduce AIDS associated 
complications and morbidity associated with HIV infection 
There is no study documenting the association of IL28B polymorphism in HIV infected 
individuals on ART. Based on the studies of association of IL28B polymorphism and the 
better clinical outcomes and the anti-HCV properties of IL28B, in this study we looked at the 
effect of IL28B polymorphism on IL28B production and immunological recovery in HIV 
infected individuals on ART. If there is any association of CC or TT genotype with HIV 
susceptibility and progression that can be used as a prognostic marker in HIV-1 infected 
individuals and IL28B can be used as an adjuvant to Antiretroviral Therapy. 
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3. Materials and Methods 
This study was conducted in the Department of Clinical Virology, Christian Medical College, 
Vellore between July 2013 and August 2014. Patients were recruited from whom attending 
the Infectious Diseases (Medicine I) and Dermatology and came to the virology department 
for CD4+ T cell testing and or HIV-1 viral load estimation.  
a) Approval for the study 
The approval for the study was obtained from the Institutional Review Board, CMC, Vellore 
(IRB Min No: 8237 dated 19.03.13).  
b) Sample size 
Though it is a pilot study the sample size was calculated using the EPI6 software based on a 
study on IL-28 polymorphism published from India. Taking into account the prevalence of 
the CT/TT genotype of 41% in healthy population(40) and precision of 14 with 5% α error 
the sample size was calculated as 48. 
c) Inclusion criteria: i) Patients 
1)  Individuals with documented HIV infection by WHO-NACO strategy 3.  
2) Age >18years         
3) HIV-1 infected individuals not on ART with CD4 + T cell count less than 350 cells/µl 
[eligible to initiate ART] 
4) Individuals who gave consent to be a part of the study 
ii) Controls 
Thirty age and sex matched HIV negative normal healthy individuals (for two cases one 
control was selected) who gave consent were also recruited for the study. Healthy age and sex 
matched laboratory staff or patient attendees (relatives) were recruited as controls after 
screening for HIV-1 infection using one of the NACO approved rapid test (PAREEKSHAK® 
HIV 1/ 2 Triline)  according to WHO-NACO strategy III. 
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Algorithm of study: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               
                          Patient referred to clinical virology laboratory for routine CD4+ T cell count  
     Informed consent 
     Patient Proforma 
 5 ml of blood [In addition to the sample collected for routine testing]  collected in EDTA 
tube and centrifuged at 2500rpm for 10 mins to separate the plasma. PBMC will be 
separated using Ficoll hypaque   
        Plasma 
Stored at  -70
0 
C 
Whole Blood            PBMC 
  Stored in RNA later  
IL-28B plasma level   
  IL-28B ELISA 
CD4+/CD8+ T-
cell estimation      
BD FACS (IVD) IL-28 polymorphism 
 
       PCR/RFLP 
If CD4+ T cell 
< 350 cells/mm
3 
Initiation of   
ART 
Include for the 
follow up study 
Correlation of IL-28B polymorphism with IL-28B plasma level and CD4+/CD8+ T-cell 
count 
Follow up after 6-9 months 
IL-28B ELISA 
CD4+/CD8+ T cell count 
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3.1. CD4+/CD8+ T-cell count estimation by flow cytometry : 
 
CD4+/CD8+ T cell counts were performed on blood samples collected using the BD 
FACS(IVD) kit by BD FACS count  flow cytometer (Becton Dickinson, New Jersey, U.S.A) 
i) Principle: 
The assay employs a two colour immunofluorescence method to measure the absolute T 
lymphocyte count (cells/µl of whole blood) of CD3+T cells and CD3+CD4+ T cells, 
CD3+CD8+ T cells. The reagents for detection consist of a mixture of monoclonal antibodies 
conjugated with two fluorochromes and a known number of fluorochrome integrated 
polystyrene beads. The tubes contain reagents with antibodies to CD4/CD3 and CD8/CD3. 
When whole blood is added in the tubes with the reagents, the antibodies bind specifically to 
the CD antigens on the surface of the T cells. The instrument detects the fluorescent signal 
and measures the relative size of the cells. 
 
ii) Procedure: 
Fifty µl of whole blood (with EDTA) was added to the tubes provided with premeasured 
reagents containing fluorescent labeled antibodies and incubated for 60 minutes. 50µl of 
fixative is added to the sample in the tube and vortexed. Control bead sets containing 
fluorochrome integrated polystyrene beads in four levels (zero, low, medium, high) are 
included to validate the linearity of the assay. The samples are run in the instrument after the 
controls are passed. The software analyzes and gives the printed report of CD4, CD8, total 
average CD3 cells and CD4/CD8 ratio. 
3.1. Quality control for CD4 count:  
 
All the blood samples for CD4+T cell count were collected between 8.00 a.m to 11.00 a.m in 
our laboratory to avoid the diurnal variation in the count. With every run, one sample from 
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the previous day is included as the internal quality control (IQC) samples. The samples were 
stored at room temperature (between 20° and 28°C) and analyzed within 48 hours of sample 
collection. The IQC values of a given day are compared with the previous day‘s values of BD 
FACS CD4+/CD3+ counts and percent variation calculated. Percent variation is calculated as 
follows: (count on the first day/count on the second day) -1 ×100. A sample showing more 
than 20% variation from the previous day‘s value is considered not acceptable and the 
clinical samples are retested if necessary. In addition to internal quality control we also use 
commercial stabilized blood (BD Multi-Check control, Becton, Dickinson, San Jose, CA) as 
external quality control for routine quality control testing. Our laboratory is also a 
participating External Quality Assessment Scheme (EQAS) programs under NARI/NACO. 
Under this EQAS program, every year 2 batches of QC samples sent by National AIDS 
Research Institute, Pune, India (NARI)/NACO are estimated for their CD3, CD4 values using 
the BD FACS Count system. The results obtained using our system are sent to NARI for 
evaluation. Since participation we always obtained values in acceptable range and passed the 
QC every time. 
 
3.2. Separation of PBMC using Ficoll- Paque : 
 
PBMC was separated from the whole blood sample within 24 hours of sample collection 
using Ficoll-Paque plus (GE healthcare, Uppsala, Sweden). 
PBMCs were separated from whole blood using Ficoll-Paque
TM
 PLUS (GE healthcare, 
Uppsala, Sweden). Anticoagulant-treated blood is layered on the Ficoll-Paque PLUS solution 
and centrifuged for a short period of time. Differential migration during centrifugation results 
in the formation of layers containing different cell types. The bottom layer contains 
erythrocytes which have been aggregated by the Ficoll and therefore, sediment completely 
through the Ficoll-Paque PLUS. The layer immediately above the erythrocyte layer contains 
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mostly granulocytes which at the osmotic pressure of the Ficoll-Paque PLUS solution attain a 
density great enough to migrate through the Ficoll-Paque PLUS layer. Because of their lower 
density, the lymphocytes were found at the interface between the plasma and the Ficoll-Paque 
PLUS with other slowly sedimenting particles (platelets and monocytes) as showed in figure 
11.  
 
 
Figure11 : Layers formed after centrifuge using Ficoll Paque Plus(177)  
 
The lymphocytes were then recovered from the interface and subjected to short washing steps 
with a balanced salt solution to remove any platelets, Ficoll-Paque PLUS and plasma. The 
cells were carefully retrieved. The PBMCs were stored in RNA LATER as aliquots of 100µl 
at concentration of 1x10
5
 cells at -80ºC in 1.7ml micro centrifuge tubes. 
3.2.1. Procedure: 
1. Label five centrifuge tubes with the sample number. 
2. Mix the blood sample well and pipette 3ml of whole blood into the centrifuge tube. Dilute 
the blood with 6ml PBS. Mix well to dilute the sample. 
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3. Pipette out 3ml of Ficoll-Paque into 3 separate centrifuge tubes. 
4. Carefully layer 3ml of the diluted blood sample onto the Ficoll-Paque in the three separate 
centrifuge tubes using the 1000µl reach pipette tips. 
5. Centrifuge the centrifuge tubes at 2000 rpm for 30 minutes at 20ºC.  
6. After centrifugation, three separate layers comprising of RBC at the bottom, Ficoll-Paque 
and plasma at the top are obtained. The PBMC are seen as an interphase between the Ficoll-
Paque and plasma layer. 
7. Carefully remove the plasma layer without disturbing the cells above the Ficoll-Paque. 
Aspirate the cells from all three centrifuge tubes and place them in a new centrifuge tube. 
8. Centrifuge the aspirate at 2000rpm for 10 minutes.  
9. Discard the supernatant. Add 5ml of PBS. Mix well and centrifuge at 2000rpm for 10 
minutes. 
10. Discard the supernatant. Add 1.5ml of PBS, mix well and centrifuge again at 2000rpm for 
10 minutes. 
11. Discard the supernatant. The washed cells are mixed in 400µl of PBS. 
12. The cells are stored as 1x10
5
cells/ml aliquots of 200µl mixed with 200µl of RNA Later at -
80ºC. 
3.3. IL-28 polymorphism detection –PCR-RFLP 
 
DNA extraction (Qiagen) from PBMC‘s was done using Qiamp DNA Blood Mini Kit 
(Qiagen, Hilden, Germany) as per manufacturer‘s instructions. 
 
 
78 
 
3.3.1.Procedure: 
1. Add 20µl of Proteinase K to 200µl of the sample in a 1.5ml of micro centrifuge tube. Add 
200µl of PBS with up to 2 x 10
5
 lymphocytes. 
2. Add 200µl of Buffer AL to the sample. Mix well by pulse-vortexing for 15 seconds. 
3. Incubate the above mixture at 56ºC for 10 minutes in a dry bath. 
4. Centrifuge the sample for a brief time to remove the moisture on the lids. 
5. Add 200µl of 100% ethanol to the sample and mix well by pulse-vortexing for 15 seconds. 
6. Centrifuge the sample to remove the moisture from the inside of the lids. 
7. Transfer the above mixture to a Qiagen Mini spin column which is placed on a 2ml 
collection tube. 
8. Centrifuge the Mini spin column at 8000rpm for one minute.  
9.  The flow through along with the collection tube is discarded and the mini spin column is 
placed on a fresh collection tube. 
10. Add 500µl of buffer AW1 to the mini spin column and centrifuge the sample at 8000rpm 
for one minute. 
11. Discard the collection tube with the flow through. Transfer the mini spin column onto a 
fresh collection tube. 
12. Add 500µl of AW2 buffer to the spin column and centrifuge this at 14,000 rpm for 3 
minutes. 
13. Discard the collection tube with the flow through. Transfer the mini spin column onto a 
fresh collection tube and centrifuge at 14,000 rpm for 1 minute at 4ºC. 
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14. Discard the collection tube and place the mini spin column in a 1.5ml micro centrifuge 
tube. Add 200µl of elution buffer AE to the spin column and incubate at room temperature 
for one minute. 
15. Centrifuge the above at 8000rpm for one minute.  
3.3.2. Genomic DNA quantification 
The extracted DNA was quantified spectrophotometrically using Take3, Gen5
TM
, Biotek. 
2 µl of the extracted DNA was loaded on the Take3 microplate and readings were taken 
using the Gen5
TM
 software. Both the concentration and purity of DNA was determined. 
 
3.3.3. PCR 
PCR amplification of rs12979860 and rs8099917 was performed using primers 
mentioned below in table 10: 
Table 10: Sequence details of the primers used for IL-28B SNP PCR. 
SNP Primer Name Sequence 
 rs12979860        rs60-F 5‘ GCGGAAGGAGCAGTTGCGCT 3‘ 
        rs60-R 5‘ GTGCCTTCACGCTCCGAGCA 3‘ 
rs8099917        rs17-F 5‘ CCCACTTCTGGAACAAATCGTCCC 3‘ 
        rs17-R 5‘ TCTCCTCCCCAAGTCAGGCAACC 3‘ 
Source: Sharafi et al , 2013 (178) 
 
The lyophilized primers were reconstituted using Tris EDTA (TE) buffer and stored in 
aliquots at -20
0
C.The standardization of the PCR was done using different primer 
concentration and annealing temperatures. The reaction volume and the cycling 
conditions PCR was standardized as mentioned in table 11 and 12. 
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Table 11: The volume of different reagents used in the PCR Reaction 
Hotstar Taq Master Mix 12.5(µL) 
Primer rs60f(10 pmol) 1(µL) 
Primer rs60r(10 pmol) 1(µL) 
DNA(100-300ng) 10.5(µL) 
Total 25(µL) 
 
3.3.3.1. Procedure: 
1. Separate master mix was prepared for the appropriate number of reactions with the above 
template in Clean (PCR reagent preparation) room.  
2. The master mix prepared was distributed to required number of 0.5ml PCR tubes. 
3. DNA extracts were removed from the storage area, brought to room temperature and spun 
briefly in a micro-centrifuge. 
 
4. 10.5 µl of DNA was added to make the final volume was 25 µl.  
6. Amplification reactions were carried out in Veriti 
TM
 Thermal Cycler (Applied Biosystem, 
California, USA) 
Table 12:The Cycling conditions used for the amplification of IL-28B gene. 
 
rs12979860(
o
C) 
 
rs8099917(
o
C) 
       
Time 
       
Cycles 
               95             95    15 minutes        1 
               95 
               60 
               72 
            95 
            56 
            72 
   30 seconds   
   30 seconds 
   45 seconds   
      40 
      40 
      40 
               72             72    7 minutes        1 
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Expected band size of the amplified products. 
Post PCR amplification, the products are detected by Gel electrophoresis, the gel was 
visualized by ultraviolet radiation using Quantity one® (version 4.6.2) software in the gel 
documentation system (BioRad, California, USA).The expected band size are 
rs12979860 – 241bp 
rs8099917 – 552bp 
Quality Control for IL28B SNP PCR:  
a) Positive control: A preciously known extracted DNA is amplified, the expected band 
size are as follows.  
rs12979860 – 241bp 
rs8099917 – 552bp 
b) Negative control: Milli Q water. 
 
3.3.4. Restricted Fragment Length Polymorphism (RFLP) 
The product of the PCR was used for RFLP analysis using Restriction Endonuclease 
BstUI and BsrDI (New England Biolabs®, UK). The reaction volume is as follows(table 
13& table 14). 
a) rs12979860 
Table 13: The volume of different reagents used in the RFLP 
Reagants Volume per reaction(µl) 
BstUI 2(µL) 
Cut-smart Buffer 2(µL) 
Nuclease free water 8(µL) 
Amplified product 8(µL) 
Total volume 20(µL) 
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b) rs8099917 
            Table 14: The volume of different reagents used in the RFLP 
Reagants Volume per reaction(µl) 
BsrDI 2(µL) 
NE Buffer 2(µL) 
Nuclease free water 8(µL) 
Amplified product 8(µL) 
Total volume 20(µL) 
 
The reactions for rs12979860 were incubated at 60°C for 15 minutes, and those for rs8099917 
at 65°C for 15 mins Veriti 
TM
 Thermal Cycler (Applied Biosystem, California, USA).  
3.3.4.1. Gel Documentation following RFLP 
Ten microlitres of each amplicon was mixed with 2 µL of 6X loading dye bromophenol 
blue and then subjected to electrophoresis in freshly prepared 3% agarose gel containing 
0.5 µg/ml ethidium bromide. Molecular ladder (Low range DNA Marker-A, Bio Basic 
Inc, Canada) used was 25-500 bp long. The gel was visualized by ultraviolet radiation 
using Quantity one® (version 4.6.2) software in the gel documentation system (BioRad, 
California, USA).The band size for genotypes are summarized in Table 15 
 
Table 15: The expected bands of different genotypes are as follows 
 rs12979860(band size) Genotype    rs8099917(band size) Genotype 
               241     TT                 552    TT 
             196,45     CC             322, 230      GG 
         241, 196, 45     CT          552, 322, 230    GT 
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Quality control for RFLP: 
Positive control: Previously positive samples were included 
rs12979860 – CT- bands at 241,196 and 45bp 
rs8099917 – GT- bands at 552,320 and 232bp. 
 
3.4. IL-28B plasma level estimation by ELISA:  
IL-28 plasma level was estimated by a Human IL-28B in-house quantitative ELISA kit (R&D 
Systems, Minneapolis, MN, USA)[Catalog Number: DY5259] as per manufacturer‘s 
instructions.  
Principle:  
The system utilizes quantitative technique of ―Sandwich‖ ELISA  where  the  target  protein  
(antigen)  is  bound  in  a  ―sandwich‖  format  by  the  primary  capture  antibodies  coated  to  
each  well-bottom  and  the  secondary  detection  antibodies  added  subsequently by the 
investigator. The capture antibodies coated to the bottom of each well are specific for a particular 
epitope on the Human IL-28B cytokine, while the user-added detection antibodies bind to 
epitopes on the capture target protein.  
 
3.4.1.1. Procedure for PBS preparation. 
1. Dissolve the salts in distilled water and make up the volume to 1000ml as mentioned in table 
16. 
2. Adjust the pH to 7.4 with 1N NaOH. 
3. Autoclave at 121ºC for 15 min at 15lb. 
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4. The autoclaved solution is stored at 4ºC. For every use PBS is diluted with sterile MilliQ water 
to a dilution that is one in tenth of the original concentration. The pH is checked and adjusted 
before every use. 
3.4.1.Preparation of phosphate buffered saline(PBS)  
 
Table 16: Materials used in preparation of PBS 
Materials Quantity 
NaCl 8gm 
KCl 0.2gm 
NA2HPO4 1.15gm 
KH2PO4 0.2gm 
Distilled water 1000mL 
 
Reagant Diluent: 1% Bovine Serum Albumin is added to 1x phosphate buffered saline. Reagant 
Diluent. 
Wash Buffer: 0.05% Tween®20 in PBS, pH 7.2-7.4 in 1x phosphate buffered saline  
 
3.4.2. Procedure for ELISA 
Plate Preparation: 
1) Capture Antibody (mouse anti-human IL-28B) is diluted to the working concentration of 
2µg/mL in 1x Borate Buffer. Immediately coat a 96-well microplate with 100µL per well of the 
diluted Capture Antibody. Seal the plate and incubate overnight at 4
0
C. 
2) Each well is aspirated and washed with 400µL of wash buffer three times using automated 
washer ( Biotek, Winooski, USA) and blotted against clean paper towel. 
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3) 300µL of reagent diluent is added to each well for blocking and incubated at room 
temperature for a minimum of one hour. 
4) Aspiration and wash step is repeated as in step 2 
Assay procedure:  
1)  Standards (recombinant human IL-28B) reconstituted in reagent diluent containing 
recombinant human IL28B is diluted in seven 2-fold serial dilutions of with high standard being 
2000pg/mL followed by 1000, 500, 250, 125, 62.5, 31.25 pg/mL was used. 
2) 100µL of sample and standards in reagent diluent is added. The plate is covered with adhesive 
strip and incubated for 2 hours at room temperature. 
3) After the aspiration/wash as in step 2 of plate preparation, 100µL of the Detection Antibody 
diluted in reagent diluent to working concentration of 500ng/mL is added to each well. Cover 
with a new adhesive strip and incubate for 2 hours at room temperature. 
4) After the aspiration/wash as in step 2 of plate preparation, 100 µL of working concentration of 
Streptavidin-HRP(1:200) in reagent diluent was added to each well. Cover the plate and 
incubated for 20 minutes at room temperature avoiding the plate to direct light. 
5) After the aspiration/wash step as in step 2 of plate preparation,100 µL of 1:1 mixture of 
Tetramethylbenzidine(TMB) and H2O2 is added to each well and incubated for 20 minutes at 
room temperature avoiding direct light. 
6) 50µL of stop solution(2N H2SO4) is added to each well. 
7) The optical density of each well is determined using microplate reader (Biotek®, Winooski, 
USA) by taking reading  using dual wavelength of 450nm and 570nm. 
 
Calculation of results 
The average of concentration for each sample was calculated. Using standards in 7 dilutions and 
zero standard, a 4-Parameter logistic(4-PL) curve was generated with concentrations on X-axis 
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and Delta OD values on Y-axis using Gen5 software and concentration in each clinical sample 
was calculated based on Delta OD. 
 
Statistical analysis 
 
Continuous variables like CD4, CD8, CD3 counts and CD4/CD8 ratio were reported as mean ± 
standard deviation or median.  Continuous variables of the two visits (before ART and following 
6-9 months of ART) were analyzed using paired T-test. Categorical variables were expressed as 
frequencies (%). The difference in the distribution of variables was checked using Kruskal-
Wallis equality-of-populations rank test. Independent variables were analyzed using Mann-
Whitney U-test. C hi square test was used to analyze the frequencies of IL-28B genotypes and 
haplotypes. A p value ≤ 0.05 was used as the criterion for statistical significance. All data 
generated in the study were analyzed using the MedCalc software. 
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4. Results 
 
A total of 80 HIV infected individuals from the four south Indian states who were not on 
antiretroviral therapy were recruited during July 2013 to December 2013 after approval from the 
Institutional Review Board (IRB Ref Min No 8237 dated 19.03.2013). Seven patients expired 
during the follow up, while 24 were not on ART lost to follow up. Finally 49 HIV-1 infected 
individuals who full filled the inclusion criteria who were initiated on ART and  followed up for 
6-10 months .  The mean age of these 49 individuals were 46.21 + 10.61. Majority of the 
subjects were from the state of Tamil Nadu (61.2%) with remaining from Andhra Pradesh and 
Kerala. The demographic data of the patients recruited in to the study were shown in Table 17. 
 
Table 17: Demographic details of the HIV infected individuals 
SL No  
State 
 
Total (%) 
 
Male 
 
Female 
 
Age(Mean+SD) 
1 Tamil Nadu 30(61.2%)  16 14 43 + 10 
 
2 Andhra Pradesh 18(36.7%) 12 6 42 + 10 
3 Kerala 1(2%) 1 0 51 
 
 
Controls:  
Age and Sex matched HIV sero-negative healthy controls were also recruited. All the 30 
healthy individuals were from Tamil Nadu of mean age 42years( +10) were recruited 
 
 
HIV-1 infected individuals under different antiretroviral therapy regimen 
Majority (77%) of the patients were on Zidovidue and Lamivudine with either Nevirapine 
or Efavirenz. The remaining were on Tenofovir regimen. This data is shown in table 18. 
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Table 18: Patients under different ART Regimen 
Initial ART regimen Number 
of  cases 
Zidovudine + Lamivudine + Efavirenz 
Zidovudine + Lamivudine + Nevirapine 
Tenofovir + Lamivudine + Nevirapine 
Tenofovir + Lamivudine + Efavirenz 
Tenofovir +Emtricitabine + Efavirenz 
Tenofovir + Lamivudine + Efavirenz 
Tenofovir + Emtricitabine + Efavirenz 
10 
28 
4 
4 
1 
1 
     1 
 
 
4.1. CD4+ T cell and CD8+ T cell Estimation  
4.1.1. Absolute CD4+ and CD8+ T-cell counts, CD4/CD3% and CD4/CD8 ratio 
before and after 6-9 months of ART. 
The absolute CD4+ and CD8+ T-cell counts, CD4/CD3%, CD8/CD3% and CD4/CD8 
ratio before and after 6-9 months of ART were analyzed by Paired samples T-test. There 
was a significant increase (p= < 0.001)  in the median absolute CD4+ T cell count, 
CD4/CD3% and there was significant reversal of CD4/CD8 ratio following 6-9 months of 
ART as shown in the table 19 and figure 12. 
 
Table 19: Cell counts in HIV-1 infected individuals before and after initiation of ART 
 
Parameter 
Before ART 
Median(range) 
6-9 months after ART 
Median (range) 
p-value 
CD4+ T-cell 147(4-370) 252(17-769) <0.001 
CD4/CD3% 14.3(0.5-4.5) 20.99(4.4-58.8) <0.001 
CD8+ T- cell 775(132-2000) 942(187-2000) <0.001 
CD8/CD3% 78.8(50.3-102.4) 73.54(36.9-89.3) <0.001 
Average CD3 1008(172-2759) 1367(256-3500) <0.001 
CD4/CD8 ratio 0.18(0.01-0.86) 0.28(0.06-1.6) <0.001 
89 
 
n_49
case
 Medians  (error bars: 95% CI for median)
1600
1400
1200
1000
800
600
400
200
0
CD4 CD4F CD4%CD4F% CD8 CD8F CD3 CD3F
 
Figure 12:  Bar diagram showing the significant increase in CD4+, CD4/CD3%, CD8+ T 
cell counts and total CD3+ T cell after 6-9 months of ART. 
 
4.2. IL-28B polymorphisms  
The IL-28B detection was done by PCR-RFLP as described previously with PBMC 
samples from all the 49 HIV infected individuals. The gel documentation of PCR 
amplification product of rs12979860 and rs8099917 SNP is shown in figure 13 and 14 
respectively. 
 
Figure 13: A representative gel picture with rs12979860 PCR amplification product . 
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Figure 14: A representative gel picture with rs8099917 PCR amplification product. 
 
4.2.1. RFLP 
The amplified products were used for RFLP as described previously(178). The gel 
documentation picture of rs12979860 and rs8099917 digested products of the amplicons and 
their different genotypes are shown in figure 15 and 16 respectively.  
 
Figure15: A representative gel picture of RFLP for detection of rs12979860 genotypes.  
 
 
Digested product size 
 
CC- 196bp, 45bp 
 
CT- 241bp, 196bp, 45bp 
 
TT- 241 bp 
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Figure 15: A representative gel picture of RFLP for detection of rs8099917 
genotypes. 
 
4.3. Distribution of IL-28B genotypes in HIV infected individuals 
Among the 49 HIV infected individuals the frequency of CC genotype at rs1297960 was 
found to be 32 (65%), compared to CT 15(31%) and TT 2(4%). The frequency of wild 
type CC genotype by Chi-Square test shows a significant (p= <0.001) higher frequency 
when compared to other SNPs CT and TT. The diagrammatic representation of the 
distribution of genotypes is shown in figure 16. 
 
Figure 16: Frequency distribution of rs1297960 polymorphism among HIV-1 infected 
individuals 
Digested product size 
 
TT - 552bp,  
 
GT- 552bp, 322bp,230bp 
 
GG- 322 bp, 230bp 
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 Among the 49 HIV infected individuals the frequency of TT genotype at rs8099917 was 
found to be 39(80%), compared to GT 9(18%) and GG 1(2%). The frequency of wild 
type TT genotype by Chi-Square test shows a significant (p= <0.0001) higher frequency 
when compared to other SNPs GT and GG. The diagrammatic representation of the 
distribution of genotypes is shown in figure 17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Frequency distribution of rs8099917 polymorphism among HIV-1 infected 
individuals 
 
 
 
4.3.1. Distribution of haplotypes in HIV infected individuals 
The frequency of haplotype in HIV infected individuals showed CC/TT 31(64.6%), CT/GT 
8(16.7%), CT/TT 7(14.6%), TT/GG  1(2%) and TT/GT 1(2%) as shown in figure 18.The 
frequency of wild genotype is significantly(p= <0.001) higher compared to other haplotypes 
as analyzed by Chi-Square test. 
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Figure 18: Frequency distribution of rs12979860 and rs8099917 haplotypes in HIV 
infected individuals 
 
Among the 30 controls the frequency of CC genotype at rs1297960 was found to be 
18(60%), compared to CT 10(33%) and TT 2(7%). The frequency of wild type CC 
genotype by Chi-Square test shows a significant (p= 0.005) higher frequency when 
compared to other SNPs CT and TT .The diagrammatic representation of the distribution 
of genotypes is shown in figure 19. 
 
 
Figure 19: Frequency distribution of rs1297960 polymorphism in HIV seronegative 
healthy controls 
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Among the 49 HIV infected individuals the frequency of TT genotype at rs8099917 was 
found to be 23(77%), compared to GT 7(23%) and GG 0(0%). The frequency of wild 
type TT genotype by Chi-Square test shows a significant (p= 0.02) higher frequency 
when compared to other SNPs GT and GG. The diagrammatic representation of the 
distribution of genotypes is shown in figure 20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Frequency distribution of rs8099917 polymorphism in HIV seronegative 
controls 
 
4.3.2. Distribution of haplotype in HIV seronegative controls 
The frequency of haplotype in controls showed CC/TT 15(52%), CT/TT 7(24%), CT/GT 
3(10%), and TT/GT 1(4%) as shown in figure 21. The frequency of wild genotype is 
significantly (p= <0.001) higher compared to other haplotypes as analyzed by Chi-Square 
test. 
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Figure 21: Frequency distribution of rs12979860 and rs8099917 haplotypes in controls 
 
 
4.4. Association of TT/GG with Immune reconstitution inflammatory syndrome 
 
Out of 49 HIV infected individuals recruited, a 65 years old female from Andhra Pradesh 
on Zidovudine, Lamivudine and Nevirapine, reported with Immune reconstitution 
inflammatory syndrome and Pneumocystis carinii pneumonia following 1 month of ART. 
PCR-RFLP revealed homozygous TT genotype of rs12979860 SNP and homozygous GG 
genotype of rs8099917 SNP. Table 20 summarizes the CD4 counts before ART, on 
presentation IRIS symptoms and follow up. 
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Table 20: CD4/CD8 estimation and IL-28B plasma level before ART, during IRIS and 
Follow-up 
 Absolute 
CD4+(cell
s/µL)  
CD4/CD3% Absolute 
CD8+(cells/
µL) 
CD8/CD3% CD4/CD8 
ratio 
IL-28B 
Plasma 
(pg/mL) 
Before 
ART 
48 4.92 874 89.55 0.05 137.7 
IRIS 43 12.32 290 83.09 0.15 16.15 
Follow-up 107 9.58 975 87.29 0.11 0 
Follow-
up2 
186 8.51 1996 91.31 0.09 3.80 
  
4.5. The frequency distribution of the IL-28B genotypes in HIV infected individuals 
and controls 
The frequency distribution of the IL-28B genotypes in HIV infected individuals and 
controls are summarized in the table 21. 
 
Table 21: Frequency and percentage of IL28B polymorphisms in cases and controls 
IL-28B 
polymorphism 
Control (n=30) 
n (%) 
p-value HIV infected 
individuals 
(n=49) 
 n(%) 
 
p-value 
rs12979860 
 CC 
 CT 
 TT 
 
18(60) 
10(33) 
2(7) 
 
 
 
<0.001 
 
32(65) 
15(31) 
2(4) 
 
 
<0.001 
rs8099917 
 TT 
 GT 
 GG 
 
 
23(77) 
7(23) 
0(0) 
 
 
 
 
<0.001 
 
39(80) 
19(18) 
1(2) 
 
 
<0.001 
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4.6.1. Association of rs12979860 and rs8099917 with CD4 T-cell counts before and 
after treatment 
The association of rs12979860 and rs8099917 and the median absolute CD4+ T-cell counts 
were analyzed using Kruskal-Wallis test. It was found that these genotypes are not 
significantly associated with absolute CD4+ T-cell counts before and after ART. The 
interpretation is summarized in the table 22. 
 
Table 22: Association of rs12979860 and rs8099917 genotypes with CD4 T-cell counts 
before and after treatment 
IL-28B 
polymorphi
sm 
Cases 
(n=49) 
 n(%) 
 
Pre Rx CD4 
count Median 
(range) 
p-value 
(Pre ART) 
Post Rx CD4 
Count 
Median(range) 
p-value 
(Post 
ART) 
rs12979860 
 CC 
 CT 
 TT 
 
32(65) 
15(31) 
2(4) 
 
173.5(4.0-37) 
138.0(13-27) 
62(48-76) 
 
  
 0.8 
 
345(64-769) 
242(17-453) 
166(107-225) 
 
 
0.1 
 
rs8099917 
 TT 
 GT 
 GG 
 
 
39(80) 
9(18) 
1(2) 
 
156.0(4-37) 
111.50(13-24) 
122.50(48-19) 
 
 
0.4 
 
275(64-769) 
242(17-453) 
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0.5 
 
 
4.6.2. Association of genotypes with absolute CD4+ T-cell count 
The association of wild type genotypes CC and CT or TT at rs12979860 and TT and GT or 
GG at rs8099917 with the median absolute CD4 counts before and after 6-9 months of ART 
was analyzed  by using Kruskal- Wallis test. The central box represents the values from the 
lower to upper quartile (25 to 75 percentile). The middle line represents the median. The 
horizontal line extends from the minimum to the maximum value, excluding the outliers 
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which are displayed as separate points. The wild genotype CC at rs12979860 showed a 
significant (p-value = 0.03) higher CD4+ T cell count when compared to other genotypes CT 
and TT. The absolute CD4+ T-cell counts in comparison to genotypes are represented by box 
and whisker in Figure 22. 
 
 
 
 
 
 
 
 
 
   (a) (b) 
Figure 22: Box and whisker showing the association of CC genotype CD4+ T-cell 
counts before(a) and after(b) 6-9 months of ART. 
 
4.6.3. Association of haplotypes with absolute CD4+ T-cell count. 
 
The haplotypic association of wild type haplotypes CC/TT and CT/GT, CT/TT, TT/GT and 
TT/GG at rs12979860 and rs8099917 with median absolute CD4 counts before and after 6-9 
months of ART was analyzed by using Kruskal- Wallis test. The wild haplotype CC/TT 
showed a significant (p-value= 0.03) higher CD4+ T cell count when compared to other 
haplotypes.  
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The absolute CD4+ T-cell counts before and after 6-9 months of ART in comparison to 
haplotypes are represented by box whisker in Figure 23. 
 
 
 
 
 
 
 
 
 
 
Figure 23: Box and whisker showing the association of CC/TT haplotype CD4+ T-
cell counts before and after 6-9 months of ART. 
 
 
4.6.4. Association of rs12979860 and rs8099917 SNPs with CD4/CD3% T-cell counts 
before and after treatment. 
The association of rs12979860 and rs8099917 SNPs and the median CD4/CD3% counts were 
analyzed using Kruskal-Wallis test. It was found that these genotypes are not significantly 
(p= >0.05) associated with absolute CD4CD3%+ T-cell counts before and after ART. The 
interpretation is summarized in the table 23. 
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Table 23: Association of rs12979860 and rs8099917  SNPs with CD4/CD3% counts 
before and after treatment. 
IL-28B 
polymorphism 
Cases 
(n=49) 
 n(%) 
 
Pre ART 
CD4/CD3% count 
Median (range) 
p-value 
(Pre ART) 
Post Rx CD4/CD3% 
Count 
Median(range) 
p-value 
(Post 
ART) 
rs12979860 
 CC 
 CT 
 TT 
 
32(65) 
15(31) 
2(4) 
 
16.11( 0.52-26.8) 
12.81(2.41-43.48) 
10.19(4.91-15.47)  
 
 
 
0.2 
 
24.47(7.03-58.81) 
15.84(4.44-41.06) 
22.76(9.58-35.94)  
 
 
 
0.06 
rs8099917 
 TT 
 GT 
 GG 
 
 
39(80) 
9(18) 
1(2) 
 
15.1(0.52- 26.8) 
14.32(4.37-43.48) 
4.91  
 
 
0.5 
 
21.11(6.27-58.81) 
17.25(4.44-35.94) 
9.58 
 
 
0.3 
 
 
 
4.6.5. Association of genotypes with CD4/CD3% counts before and after treatment.  
The association of wild type genotypes CC and CT or TT at rs12979860 and TT and GT or 
GG at rs8099917 with median CD4/CD3% before and after 6-9 months of ART was 
analyzed by using Kruskal- Wallis test. The wild genotype CC at rs12979860 showed a 
significant (p-value= 0.03) higher CD4/CD3% when compared to other genotypes CT and 
TT. 
 The association of  genotypes with CD4/CD3% before and after 6-9 months of ART in are 
represented by box & whisker in Figure 24. 
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Figure 24: Box and whisker plot to showing the association of rs12979860 genotypes 
with CD4/CD3% counts before and after treatment.  
 
 
4.6.6. Association of rs12979860 and rs8099917 with CD8 T-cell counts before and 
after treatment 
The association of rs12979860 and rs8099917 and the median absolute CD4+ T-cell 
counts were analyzed using Kruskal-Wallis test. It was found that these genotypes are not 
significantly associated with absolute CD8+ T-cell counts before and after ART. The 
interpretation is summarized in the table 24. 
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Table 24: Association of rs12979860 and rs8099917 with CD8 T-cell counts before and 
after treatment 
IL-28B 
polymorph
ism 
Cases 
(n=49) 
n(%) 
 
Pre Rx CD8 count 
Median (range) 
p-value 
(Pre 
ART) 
Post Rx CD8 
Count 
Median(range) 
p-value 
(Post 
ART 
rs12979860 
 CC 
 CT 
 TT 
 
32(65) 
15(31) 
2(4) 
 
796(239-2000) 
674(132-1582) 
600.5(327-874 
 
 
0.3 
 
928(187-2000) 
1145(272-2000) 
600.5(327-874) 
 
  
0.1 
rs8099917 
 TT 
 GT 
 GG 
 
 
39(80) 
9(18) 
1(2) 
 
750(73.95-2000) 
698.5(132-1312) 
874 
 
 
0.4 
 
942(187-2000) 
861(298-2000) 
975 
 
 
0.4 
 
4.6.7. Association of haplotypes with CD8+ T-cell count before and after 6-9 months 
of ART 
The haplotypic  association of wild type haplotype CC/TT and the other haplotypes 
CT/GT, CT/TT, TT/GT and TT/GG at rs12979860 and rs8099917 with median absolute 
CD8+ T-cell counts before and after 6-9 months of ART by using Kruskal- Wallis test. 
No significant( p= >0.05) association was found out between haplotypes and absolute 
CD8+ T-cell count.  
The association of haplotypes with absolute CD8+ T-cell counts before and after 6-9 
months of ART are represented by box-whisker plot in Figure 25. 
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Figure 25: Box and whisker plot showing the association of haplotypes with absolute 
CD8+ T-cell count before and after 6-9 months of ART. 
 
4.6.8. Association of rs12979860 and rs8099917 with CD8/CD3% counts before and 
after treatment 
 
The association of rs12979860 and rs8099917 and the absolute CD8/CD3% counts were 
analyzed using Kruskal-Wallis test. It was found that these genotypes are not 
significantly associated with absolute CD8/CD3% counts before and after ART. The 
interpretation is summarized in the table 25 below. 
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Table 25:  Association of rs12979860 and rs8099917 SNPs with CD8/CD3% T-cell 
before and after treatment. 
IL-28B 
polymorphism 
Cases 
(n=49) 
n(%) 
 
Pre Rx CD8/CD3% 
count 
Median (range) 
p-value 
(Pre ART) 
Post Rx CD8/CD3% 
Count Median(range) 
p-value 
(Post 
ART 
rs12979860 
 CC 
 CT 
 TT 
 
32(65) 
15(31) 
2(4) 
 
77.62(57-102.41) 
81.84(50.33-96.1) 
78.07(66.59-89.54) 
 
 
0.5 
 
72.6(36.86-88.5) 
75.05(51.71-89.3) 
72.24(57.19-87.29) 
 
   
0.5 
rs8099917 
 TT 
 GT 
 GG 
 
 
39(80) 
9(18) 
1(2) 
 
78.66(57-102.41) 
79.32(50.33-84.53) 
89.54 
 
 
 
0.4 
 
73.54(36.86-89.3) 
72.79(57.14-79) 
87.29 
 
 
0.2 
 
4.6.9 Association of rs12979860 and rs8099917 SNPs with CD4/CD8 ratio before and 
after treatment. 
 
The association of rs12979860 and rs8099917 SNPs and median CD4/CD8 ratio were 
analyzed using Kruskal-Wallis test. It was found that these genotypes are not 
significantly associated with median CD4/CD8 ratio before and after ART. The 
interpretation is summarized in the table 26. 
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Table 26:  Association of rs12979860 and rs8099917 SNPs with CD4/CD8 ratio before 
and after treatment. 
IL-28B 
polymorphism 
Cases 
(n=49) 
n(%) 
 
Pre Rx CD4/CD8 
count 
Median (range) 
p-value 
(Pre ART) 
Post Rx CD4/CD8 
Count Median(range) 
p-value 
(Post 
ART 
rs12979860 
 CC 
 CT 
 TT 
 
32(65) 
15(31) 
2(4) 
 
0.19(0.01-0.38) 
0.16(0.03-0.86) 
0.14(0.05-0.23) 
 
 
0.5 
 
0.32(0.06-1.6) 
0.22(0.06-0.79) 
0.37(0.11-0.63) 
 
 
0.3 
rs8099917 
 TT 
 GT 
 GG 
 
 
39(80) 
9(18) 
1(2) 
 
0.17(0.01-0.38) 
0.23(0.06-0.63) 
0.05 
 
 
0.1 
 
0.28(0.06-1.6) 
0.24(0.06-0.63) 
0.11 
 
0.4 
 
4.6.10. Association of haplotypes with CD4/CD8 before and after 6-9 months of 
ART. 
 
The haplotypic association of wild type haplotypes CC/TT and CT/GT, CT/TT, TT/GT 
and TT/GG at rs12979860 and rs8099917 SNP with median CD4/CD8 ratio before and 
after 6-9 months of ART was analyzed by using Kruskal- Wallis test. No significant ( p= 
>0.05) association was found out between haplotypes and CD4/CD8 ratio. The 
association of absolute CD8+ T-cell counts before and after 6-9 months of ART in with 
the haplotypes are represented in a Box and whisker plot in Figure 26. 
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Figure 26: Box and whisker showing the association of haplotype with the CD4/CD8 
ratio before and after initiation of ART. 
 
4.7. IL-28B plasma level estimation 
 
IL-28 plasma level was estimated by a Human IL-28B in-house quantitative ELISA kit (R&D 
Systems, Minneapolis, MN, USA) [Catalog Number: DY5259] as per manufacturer‘s 
instructions as described in the methods.  
 
Calculation of concentration 
The average of concentration for each sample was calculated. Using standards in 7 dilutions and 
zero standard, a 4-Parameter logistic(4-PL) curve was generated with concentrations on X-axis 
and Delta OD values on Y-axis using Gen5 software as shown in figure 27 and the curve fit 
results are shown in table 27. 
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Figure 27: A representative picture of 4-Parameter Logistic (4-PL) Curve constructed for 
standards with 7 dilutions using Gen5 software performed in this study. 
 
Table 27: A representative curve fit results calculated by Gen5 software. 
Curve 
Name 
Curve Formula A B C D R2 
IL28B 
Curve 
Y = (A-
D)/(1+(X/C)^B) + D 
0.155 1.24 2.29E+04 33.5 1 
 
Validation of ELISA: 
The inter-assay variation was calculated based on readings of 5 days. The Co-efficient of 
variation (CV%)  calculated for standards of concentrations 500pg/ml, 125pg/ml and 62.5pg/ml 
were 2.3%, 12.7% and 37.5% respectively.   
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4.7.1. Association of rs12979860 and rs8099917 SNPs with IL-28B plasma level  
before and after 6-9 months treatment in HIV infected individuals. 
The association of rs12979860 and rs8099917 SNPs with median IL-28B plasma level 
were analyzed using Kruskal-Wallis test. It was found that these genotypes were not 
significantly (p = >0.05) associated with median IL-28B plasma level before and after 
ART. The interpretation is summarized in the table 28. 
Table 28: Association of rs12979860 and rs8099917 genotypes with IL-28B plasma level 
before and after treatment 
 
IL-28B 
polymorphism 
Cases 
(n=49) 
 n(%) 
 
Pre ART IL-28B 
plasma level 
Median (range) 
p-value 
Pre 
ART 
Post ART IL-
28B plasma 
Level 
Median(range) 
p-value 
Post 
ART 
rs12979860 
 CC 
 CT 
 TT 
 
32(65) 
15(31) 
2(4) 
 
68.75(0.0-221.26) 
91.54(0-524.48) 
75.19(12.65-137.74) 
 
 
0.5 
 
69.82(80-490.25) 
30.85(0-394.3) 
0(0) 
       
 
0.1 
 
rs8099917 
 TT 
 GT 
 GG 
 
 
39(80) 
9(18) 
1(2) 
 
59.06(0.0-514.48) 
129.5(912.65-236.46) 
137.73 
 
 
0.3 
 
61.83(0-490.25) 
30.850(0-207.13) 
0 
 
 
0.2 
 
 
4.7.2. Association of rs12979860 genotypes with IL-28B plasma level in HIV infected 
individuals. 
The association of rs12979860 genotypes with median IL-28B plasma level was analyzed 
using Kruskal-Wallis test. It was found that these genotypes are not significantly (p = >0.05)  
associated with median IL-28B plasma level before and after ART. Box and whisker showing 
the association of rs12979860 with IL-28B plasma level is shown in figure 28. 
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Figure 28: Box and whisker plot to look at the association of genotypes of rs12979860 
with IL-28B plasma level in HIV infected individuals. 
 
4.7.3.Association of rs8099917 with  IL-28B plasma level in HIV infected individuals 
The association of rs8099917 genotypes with median IL-28B plasma level was analyzed 
using Kruskal-Wallis test. It was found that these genotypes are not significantly (p = >0.05) 
associated with IL-28B plasma level before and after ART. Box and whisker showing the 
association of rs809917 with IL-28B plasma level is shown in figure 29. 
 
 
 
 
 
 
 
 
Figure 29: Box and whisker plot to look at the association of genotypes of rs8099917 
with IL-28B plasma level in HIV infected individuals. 
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4.7.4. Association of haplotype CC/TT and other haplotypes with IL-28B plasma level in  
HIV infected individuals before ART. 
The association of haplotypes with median IL-28B plasma level was analyzed using Kruskal-
Wallis test. It was found that they are not significantly (p = >0.05) associated with median 
IL-28B plasma level before ART. Box and whisker showing the association of haplotypes 
with IL-28B plasma level is shown in figure 30. 
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Figure 30: Box and whisker showing the association of haplotype CC/TT and other 
haplotypes with IL-28B plasma level in HIV infected individuals. 
 
4.7.5. Association of haplotype CC/TT and other haplotypes with IL-28B plasma level in  
HIV infected individuals  after 6-9 months ART. 
 
The association of haplotypes with median IL-28B plasma level was analyzed using Kruskal-
Wallis test. It was found that they are not significantly (p = >0.05) associated with median 
p= 0.4 
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IL-28B plasma level after ART. Box and whisker showing the association of haplotypes with 
IL-28B plasma level is shown in figure 31. 
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Figure 31: Box and whisker showing the association of haplotype CC/TT and other 
haplotypes with IL-28B plasma level in HIV infected individuals. 
 
4.7.5.Association of rs12979860 SNP with IL-28B plasma level  in controls. 
 
The association of rs12979860 genotypes with median IL-28B plasma level in controls was 
analyzed using Kruskal-Wallis test. It was found that these genotypes are not significantly (p 
= >0.05) associated with median IL-28B plasma level before and after ART. Box and 
whisker showing the association of rs12979860 with IL-28B plasma level in controls is 
shown in figure 32. 
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Figure 32: Box-whisker plot comparing the IL-28B plasma levels with the genotypes at 
rs12979860 in controls. 
 
4.7.6. Association of rs8099917 genotypes with IL-28B plasma level in controls 
 
 
The association of rs8099917 genotypes with median IL-28B plasma level in controls was 
analyzed using Kruskal-Wallis test. It was found that these genotypes are not significantly (p 
= >0.05) associated with median IL-28B plasma level before and after ART. Box and 
whisker plot showing the association of rs8099917 with IL-28B plasma level in controls is 
shown in figure 33. 
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Figure 33: Box-whisker plot comparing the IL-28B plasma levels with the genotypes at 
rs8099917 in controls. 
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4.7.7. Association of haplotypes with IL-28B plasma level in controls  
 
The association of haplotypes with median IL-28B plasma level in controls was analyzed 
using Kruskal-Wallis test. It was found that these genotypes are not significantly (p = >0.05) 
associated with median IL-28B plasma level before and after ART. Box and whisker showing 
the association of haplotype with IL-28B plasma level in controls is shown in figure 34. 
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Figure 34: Box-whisker plot comparing the IL-28B plasma levels with the haplotypes in 
HIV seronegative controls. 
 
 
4.7.8. IL28B plasma level comparison between cases and control 
 
 
The association of median IL-28B plasma level in HIV infected individuals and  controls was 
analyzed using Mann-Whitney U test. There is no significant (p = >0.05) difference in IL-
28B plasma level HIV infected individuals and controls. Box and whisker showing the 
difference of IL-28B plasma level in HIV infected individuals and controls  is shown in 
figure 35. 
p=0.8 
114 
 
Box Whisker(p=0.7)
1200
1000
800
600
400
200
0
IL28B(HIV infected) IL28(controls)
 
 
Figure 35: Box-whisker plot comparing the IL-28B plasma levels in cases and controls 
 
 
4.7.9.Association of  haplotypes with  IL-28B plasma level of HIV infected individuals 
before ART 
 
The association of haplotypes with median IL-28B plasma level in HIV infected individuals 
was analyzed using Kruskal-Wallis test. It was found that these haplotypes are not 
significantly (p = >0.05) associated with IL-28B plasma level before ART. Box and whisker 
showing the association of haplotype with IL-28B plasma level in HIV infected individuals 
before ART is shown in figure 36. 
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Figure 36: Box-whisker plot comparing the IL-28B plasma levels with the haplotypes in 
HIV infected individuals. 
 
4.7.10Association of haplotypes  with IL-28B plasma level after 6-10 months of ART in 
HIV infected individuals.  
 
The association of haplotypes with median IL-28B plasma level in HIV infected individuals 
was analyzed using Kruskal-Wallis test. It was found that these haplotypes are not 
significantly (p = >0.05) associated with IL-28B plasma level after 6-10 months of ART. Box 
and whisker showing the association of haplotypes with IL-28B plasma level in HIV infected 
individuals after ART is shown in figure 37. 
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Figure 37: Box-whisker plot comparing the IL-28B plasma levels after 6-9 months of 
ART with the haplotypes in cases. 
 
 
4.8.1.Association of IL-28B plasma level with CD4 counts 
 
 
The association of IL-28B plasma level and absolute CD4+ T-cell counts were analyzed 
using Spearman‘s correlation test. R (rho value = 0.6-0.8) is significant and indicates 
positive correlation. It was found that absolute CD4+ T-cell count is not significantly (p = 
>0.05 & R= -0.142)) associated with median IL-28B plasma level before and after 
ART(p= >0.05, R= 0.256). IL-28B plasma level does not have any effect on  absolute 
CD4+ T-cell  count before ART and increase in absolute CD4+ T-cell  count  after 6-9 
months of ART. The interpretation is summarized in the figure 38. 
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Figure 38: Scatter diagram showing the Spearman’s correlation of IL28B plasma level 
with CD4+ T-cell counts before treatment and after 6-9 months of ART. 
 
4.8.2. Association of IL-28B plasma level with CD4/CD3% counts before and after 6- 10 
months of ART. 
 
The association of IL-28B plasma level and absolute CD4/CD3% counts were analyzed 
using Spearman‘s correlation test. It was found that absolute CD4/CD3% is not 
significantly (p = >0.05 & R= -0.088) associated with median IL-28B plasma level before 
and after ART (p= >0.05 & R= - 0.11). IL-28B plasma level does not have any effect on 
CD4/CD3% before ART and increase in CD4/CD3% after 6-9 months of ART. The 
interpretation is summarized in the figure 39. 
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Figure 39: Scatter diagram showing the Spearman’s correlation of IL28B plasma level 
with CD4/CD3% counts before treatment and after 6-9 months of ART. 
 
 
4.8.3. Association of IL-28B plasma level with absolute CD8+ T-cell counts before and 
after 6-9 months of ART. 
 
The association of IL-28B plasma level and absolute CD8+ T-cell counts were analyzed 
using Spearman‘s correlation test. It was found that absolute CD8+ T-cell count is not 
significantly (p = >0.05 & R= -0.057) associated with median IL-28B plasma level before 
and after ART(p=>0.05 & R = - 0.244). IL-28B plasma level does not have any effect on 
absolute CD8+ T-cell count before ART and increase in absolute CD8+ T-cell  count  
after 6-9 months of ART. The interpretation is summarized in the figure 40. 
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Figure 40: Scatter diagram showing the Spearman’s correlation of IL28B plasma level 
with CD8+ T-cell counts before treatment and after 6-9 months of ART. 
 
 
4.8.4.Association of IL-28B plasma level with CD8/CD3% counts 
 
 
The association of IL-28B plasma level and absolute CD4/CD3% counts were analyzed using 
Spearman‘s correlation test. It was found that absolute CD4/CD3% is not significantly (p = 
>0.05 & R= -0.087) associated with median IL-28B plasma level before and after ART( p= 
>0.05 & R= -0.249). IL-28B plasma level does not have any effect on CD4/CD3% before 
ART and increase in CD4/CD3% after 6-9 months of ART. The interpretation is summarized 
in the figure 41. 
 
 
 
 
 
 
 
(p=0.2937, R= -0.152)
0 100 200 300 400 500 600
2000
1500
1000
500
0
IL28B(pg/mL)
C
D
8
(c
e
ll
s/
µ
L
)
 
(p=0.9145, R= -0.016)
0 100 200 300 400 500
2000
1500
1000
500
0
IL28B Follow-up(pg/mL)
C
D
8
 F
o
ll
o
w
-u
p
(c
e
ll
s
/µ
L
)
 
p= 0.2 
R= - 0.057 
p =0.9 
R= - 0.244 
120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: Scatter diagram showing the Spearman’s correlation of IL28B plasma level 
with CD8/CD3% counts before treatment and after 6-9 months of ART. 
 
4.8.5.Association of IL-28B plasma level with CD4/CD8 ratio before and after 6-9 
months of ART in HIV infected individuals. 
 
The association of IL-28B plasma level and absolute CD4/CD3% counts were analyzed 
using Spearman‘s correlation test. It was found that absolute CD4/CD3% is not 
significantly (p = >0.05 & R= -0.001) associated with median IL-28B plasma level before 
and after ART (p=>0.05 & R= - 0.042). The interpretation is summarized as scattered 
plot in the figure 42. 
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Figure 42: Scatter diagram showing the Spearman’s correlation of IL28B plasma level 
with CD4/CD8 ratio before treatment and after 6-9 months of ART. 
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5. Discussion 
 
Infection with HIV continues to be one of the major causes of mortality and morbidity 
especially in developing countries where the prevalence is high. The estimated number of 
people living with HIV worldwide is 35.3 million. As per the 2012 WHO report there are 
about 2.3 million newly infected individuals at the same time  AIDS related deaths  account 
for 1.6 million (2). The infection spreads through sexual, parenteral and from an infected 
mother to child. The progression of HIV disease is marked by progressive loss of CD4+ T 
cells, leading to AIDS and finally death. There are several innate and host factors that can 
affect the progression of the infection to AIDS(5).  Anti Retroviral Therapy (ART) is the only 
treatment available to inhibit the viral replication, hence reducing the AIDS related mortality 
and morbidity through immune reconstitution.  The response to ART is promising, when 
ART was introduced in India in 2004, the prevalence of HIV fell from 0.39% to 0.27% 
according to NACO annual report 2012-13, thus proving its major role in reducing the 
disease burden.  
The CD4 + T cell and the HIV-1 viral load are the two independent predictors of the disease 
progression in an infected individual(179). Several studies have documented that compared 
to the zero percentage of five year risk of progression in an infected individual with CD4+ T 
cell counts of > 500 cells/ul the 5 year risk in an individual with a CD4+ T cell count of < 
200 cells/ul is 81%(180).  It is also documented that CD4 + T cell percentage is a better 
marker than the absolute count in individuals in whom CD4+ T cell count is > 350 cells/ul 
while in those with < 350 cells / ul.  Another important factor that can affect the progression 
is the immune activation leading to higher number of activated T cells that can easily get 
infected by HIV(180). 
There are several genetic factors that can also affect the rates of disease progression in 
treatment naïve HIV infected individuals. Among them the most important one identified is  
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HLA genotype. There are reports which associated  rapid progression of the disease to AIDS 
among individuals with HLA alleles A24, B35, B37, B56, B58S and A1-B8-DR3 while  
long-term no progression is associated with  HLA alleles B57, B27, B14 and C8(129).Other   
two important genetic factors well studied are  CCR5-Δ32 and polymorphism in the gene 
encoding SDF1.  In a  multivariate logistic regression model it is reported that HIV infected 
individuals based on the presence or absence of  heterozygous  CCR5-Δ32, homozygous 
SDF1 and positive for HLA-B27 without HLA-DR6  but with at least three other HLA 
alleles (-A3, -B14,-B17, or -DR7) can be correctly classified as long-term nonprogressors (70 
percent) or progressors (81 percent)(181). Yet another meta analysis showed that individuals 
with CCR5-Δ32 and CCR2-64I alleles had a lower level of viral load following 
seroconversion and there is a reduction in the risk towards to AIDS or death(182)  
Recently there is lot of interest shown with the role of IL28B haplotype following the 
publication of 4 land mark study in 2009 showing that this can strongly affects the immune 
response in hepatitis C virus-infected patients. 
Ge et al,(2009), 1,137 patients of the previously conducted IDEAL study were recruited , the 
genotype detection was done by Illumina Human610-quad BeadChip .  They found that, in 
patients of European ancestery,  African-Americans and Hispanic population the CC 
genotype is associated with a greater rate of SVR than the TT genotype(9). 
Suppaiah et al, (2009) carried out a genome-wide association study (GWAS) of sustained 
virological response (SVR) to PEG-IFN-α/RBV combination therapy in 293 Australian 
individuals infected with genotype 1 hepatitis C virus (HCV). Among these 162 were non -
responders and the remaining 131 were responders. They concluded that the rs8099917 G 
allele predicts non-response with sensitivity of 57% and specificity of 63%. The homozygous 
GG allele was associated with non response with a positive predictive value (failure to 
respond) of 64%(8). 
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In yet another genome-wide association study among 154 Japanese patients who were 
infected with HCV genotype 1 and non responders to PEG-IFN-α/RBV combination therapy 
showed that the G allele and T allele at the rs8099917 SNP was significantly associated with 
nil virological response(144). 
Thomas et al(2009), in a GWAS  assessed the association of rs12979860 SNP in 1008 
individuals from 6 independent HCV cohorts. Among these individuals 388 were cleared the 
virus while remaining 620 were with persistent infection.  The authors concluded that the 
protective effect of C is primarily recessive, as no significant difference was observed 
between the C/T and T/T genotypes among African Americans, Caucasians, or combined 
ethnic groups for clearance of HCV.  The C/C genotype was consistently protective relative 
to C/T and/or T/T.   HCV clearance was observed much more frequently than expected 
(53%) in the C/C group(183). 
With these background information from all these HCV related studies our overall aim of the 
study was to explore the same kind of immune response in HIV infected individuals as well 
as HIV also is an RNA virus like HCV.  Towards this we recruited 49 treatment naïve HIV-1 
infected individuals who were eligible for ART initiation as there CD4+ T cell count was < 
350 cells/ul.  These individuals were followed up with  one estimation of CD4+/CD8+/CD3+ 
T cell count following treatment in the next 6-10 months. Subsequently these cell counts, 
prior to and after treatment, IL-28 polymorphism and Il-28 plasma level were analyzed to see 
any association between immune reconstitution IL-28Bgenotype/haplotype at two positions; 
rs12979860 and rs8099917rs, In order to avoid too much bias in genetic background we have 
selected only subjects belong to the south Indian states as there were evidence that 
individuals from these states are genetically close(184). In order to look at whether these 
polymorphism has got any association with the susceptibility to HIV infection we also 
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recruited 30 age and sex matched HIV negative healthy controls who belongs to the south 
Indian states. 
The IL-28B polymorphism was detected using PCR-RFLP method for genotyping of IL28B 
rs12979860 and rs8099917 SNPs is a cost effective method(185).The genotypes were 
obtained as CC,CT and TT of rs12979860 and TT,GT and GG of rs8099917 SNPs based on 
the digested products after treatment with restriction enzymes. In this study, among the HIV 
infected individuals the genotype frequency of the SNP rs12979860 CC genotype (wild) was 
higher 32 (65.3%) compared with 15(30.6%) of CT and 2(4.1%) TT genotypes. The 
frequency of SNP rs8099917 TT genotype (wild) was higher 39(79.6%) compared with 
9(18.4%) of GT and 1(2%) of GG genotypes.   
Among the 30 healthy controls in our study the genotype frequency of SNP rs12979860 CC 
genotype was higher 18(60%) compared with 10(33.3%) of CT and 2(6.7%) of TT 
genotypes. The frequency of SNP rs8099917 TT genotype was 23(76.7%) compared with 
7(23.3%) of GT and GG genotype was not reported. The frequency distribution observed for 
SNP rs8099917 in our study for genotypes   TT, GT were 76.7% 23.3% respectively. There 
were no individuals with G/G genotype observed in our HIV seronegative controls.  The 
above frequency in the distribution of IL-28B genotypes in south Indian population is similar 
to another study which was conducted in Andhra Pradesh(186). The frequency reported out 
of 220 subjects recruited in that study was CC(59.09%), CT(34.09) and TT(6.81) for SNP 
rs12979860(186). In the study reported in this thesis there was no significant differences  
found in the distribution of IL-28B polymorphism at both the SNPs between HIV infected 
individuals and healthy controls ( p = < 0.5). Frequency of haplotype in HIV infected 
individuals showed following distribution ; CC/TT 32(64.6%), CT/GT 8(16.7%), CT/TT 
7(14.6%), TT/GG  1(2%) and TT/GT 1(2%).   
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The frequency of haplotypes in HIV seronegative controls were CC/TT 15(50%), CC/GT 3 
(10%), CT/GT 3(10%), CT/TT 7(23.3%), TT/GT 1(3.3%) and TT/TT 1(3.3%).  The 
frequency observed is similar to studies within India and outside. 
 Firdaus et al (2014), a study conducted in Kolkata, India reported that among the 400 HCV 
infected patients CC, CT and TT genotype at rs12979860 was seen in 70.75%, 24% and 
5.25% respectively. The TT, GT and GG genotypes at rs8099917 was 77.5%, 15% and 
7.50% respectively among the HCV infected patients. Among the 100 healthy controls in this 
study CC, CT and TT at rs12979860 was seen in 73%, 23% and 4% respectively and TT, GT 
and GG at rs8099917 was seen in 70%, 30% and 0% respectively(10). 
Gupta et al (2014), a study conducted in New Delhi, India showed that among the HCV 
infected patients the distribution of CC, CT and TT at rs12979860 was 58.3%, 34.5% and 
7.2%. The distribution among healthy controls was CC, CT and TT at rs12979860 was 
60.6%, 35.2% and 4.2% respectively(158). 
In an Iranian population the reported frequency of the  rs12979860 CC, CT and TT genotypes 
were 40.4%, 47.1% and 12.5% and the frequency of the rs8099917 TT, GT and GG 
genotypes were 59.6%, 35.6% and 4.8%, respectively(190).  
Studies reporting the effect of IL-28B polymorphism in HIV infected individuals are limited. 
Previous work by Sajadi et al,(2008) showed that IL-28B SNP was not associated with 
spontaneous HIV control in African American individuals(12). The frequency of the CC 
genotype was 12.5% in the Natural Virological Suppressors, 14.7% in the Low Viral Load 
cohort with 400–20,000 HIV-1 RNA copies/ml, 17.8% in the Medium High Viral Load 
cohort with >20,000 HIV-1 RNA copies/ml and 11.6% in an HIV-negative cohort. There was 
no statistical significance (p=.48) in the CC genotype distribution between these cohorts. 
There was no association observed between CC genotype distribution and HIV RNA viral 
load. 
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Salgado et al,(2011) showed that CC genotype of rs12979860 SNP does not contribute to 
HIV-1 control in a cohort of African–American elite controllers/suppressors(187). A cohort 
of 25 African-American elite controllers/suppressors, of whom 13 were seropositive for HCV 
were studied.  Two of five patients who cleared HCV infection were positive for the C/C 
IL28B genotype. Overall, only 4 of 25 elite controllers/suppressors were positive for C/C 
genotype. This frequency was similar to that seen in HIV-1-infected patients with viral loads 
more than 10 000 copies/ml and seronegative patients at high risk for HIV infection in the 
ALIVE cohort. Similar frequencies were reported in other cohorts of HCV-infected African–
Americans. There was lack of over representation of the protective C/C genotype in elite 
controllers/suppressors compared with HIV-1-infected patients with substantial levels of 
HIV-1 viremia which suggested that the IL28B SNP does not play a significant role in the 
elite control of HIV-1 replication. 
Martin et al (2010) showed that the CC genotype of rs12979860 SNP does not affect the rate 
of CD4 +T-cell decline in HIV-1-infected patients. It not known whether it plays a role in the 
elite control of HIV-1 replication(151). The study included 226 individuals with HBV 
persistence, 384 with HBV recovery, and 2548 with or at high risk for HIV infection. They 
found out that the C/C genotype of rs12979860 was not associated with HBV recovery (odds 
ratio, 0.99), resistance to HIV infection (odds ratio, 0.97), or HIV disease progression ( P 
>0.05). Hence they concluded that the IL28B single-nucleotide polymorphism affects the 
immune response to HCV but not to HBV or HIV. 
The first study that showed a significant association between CC genotype  and spontaneous 
control of HIV was by MachMach et al, (2013).There was no significant difference in viral 
load set point among the CC genotype and the CT, TT genotypes(188). In our study viral 
load estimation was not done as the primary objective of our study was to look at the effect 
of these polymorphisms on immune recovery and also the high cost involved with RNA 
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estimation.   It is a well known fact that in HIV infected individuals at the end of 24 weeks ( 
6 months) following ART there will not be any detectable viral RNA (5).  However, 
estimation of the viral load prior to treatment could have given any association of IL-28 
polymorphism and HIV-1 viral load.   
In our study, the absolute CD4 + and CD8+ T-cells, CD4/CD8 were estimated both during 
recruitment and after 6-9 months of ART. There was a significant increase (p=< 0.0001 )  in 
the absolute CD4+ & CD8+T cell count, CD4/CD3% and reversal of CD4/CD8 ratio 
following 6-9 months of ART among HIV infected individuals as expected. This was well 
described in the literature(180). 
There was no significant (p=>0.05) association between the rs12979860 SNP and the 
absolute CD4+ and CD8+ T-cell, CD4/CD3% and CD8/CD3% and CD4/CD8 ratio before 
initiation of ART.  There was no significant (p= >0.05) association between the rs12979860 
SNP and the increase in absolute CD4+ and CD8+ T-cell, increase in CD4/CD3% and  
decrease in CD8/CD3% and reversal of CD4/CD8 ratio after 6-9 months of ART.  
However, the genotypic analysis showed that there is a significant(p = 0.03) association of 
CC genotype at rs12979860  when compared to other genotypes(C/T and T/T) with higher 
CD4+ T-cell count among treatment naïve HIV infected individuals and was also 
significantly (p= 0.05) associated with  higher CD4+ T-cell count following 6-9 months of 
ART.  
There was a no significant(p = >0.05) association of CC genotype at rs12979860  when 
compared to other minor genotypes(C/T and T/T) with CD8+ T-cell count among treatment 
naïve HIV infected individuals and was also not significantly (p= >0.05) associated with 
increase in CD8+ T-cell count following 6-9 months of ART. 
There is a no significant(p = >0.05) association of CC genotype at rs12979860  when 
compared to other minor genotypes(C/T and T/T) with CD8/CD3% count among treatment 
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naïve HIV infected individuals and was also not significantly (p= >0.05) associated with 
decrease in CD8/CD8% count following 6-9 months of ART.  
There is a no significant(p = >0.05) association of CC genotype at rs12979860  when 
compared to other minor genotypes(C/T and T/T) with CD4/CD8 ratio among treatment 
naïve HIV infected individuals and was also not significantly (p= >0.05) associated with 
reversal of CD4/CD8 ratio following 6-9 months of ART. The genotypic analysis of 
rs12979860 showed  there is no significant(p = >0.05) association between the absolute 
CD4+ and CD8+ T-cell, CD4/CD3% and CD8/CD3% and CD4/CD8 ratio before initiation of 
ART. There was no significant (p= >0.05) association between the rs8099917 SNP and the 
increase in absolute CD4+ and CD8+ T-cell, increase in CD4/CD3% and  decrease in 
CD8/CD3% and reversal of CD4/CD8 ratio after 6-9 months of ART. One of the biases that 
could have had at this finding may be because of the predominance of the CC genotype in the 
population. However if that is the case this significance could have for both SNPs at   
rs8099917 and  rs129779860 SNP. Since it is present only with SNP this may be a true 
association.          
In our haplotypic analysis we found that there was a significant (p=0.03) association of 
CC/TT haplotype of rs 12979860/rs8099917  ( % ) when compared to other haplotypes  
[(CT/GT) %  and CT/TT)  with higher CD4+ T-cell count among treatment naïve HIV 
infected individuals and was also significantly (p= 0.05) associated with  higher CD4+ T-cell 
count following 6-9 months of ART. There was no significant (p = 0.1) association of CC/TT 
haplotype when compared to other haplotype with higher CD4/CD3% among treatment naïve 
HIV infected individuals, However they were associated with significant (p=0.03) higher 
CD4/CD3% compared to other haplotypes following 6-9 months of ART.  
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There was a no significant(p = >0.05) association of haplotypes with CD8+ T-cell count  and 
CD8/CD3% among treatment naïve HIV infected individuals and was also not significantly 
(p= >0.05) associated with increase in CD8+ T-cell count and decrease in CD8/CD3% 
following 6-9 months of ART. There is a no significant (p = >0.05) association of haplotypes 
with CD4/CD8 ratio among treatment naïve HIV infected individuals and was also not 
significantly (p= >0.05) associated with reversal of CD4/CD8 ratio following 6-9 months of 
ART.  
Out of 49 HIV infected individuals, one individual with a TT/GG haplotype presented with 
Immune reconstitution inflammatory syndrome (IRIS) with Pneumocystis carinii pneumonia. 
IRIS usually occur when the ART is initiated when the  individual‘s CD4+ T cell count is 
very low and in this individual it was less than < 50 cells/ul.  Whether individuals with 
homozygous haplotype at both the position are prone to get IRIS needs  further investigation. 
The influence of the IL-28B SNP on IL-28B (IFN-λ3) production and activity are still 
unknown. Suppaiah et al,(2009) reported that the T/T haplotype of rs8099917encompasses a 
region likely to affect expression of IL28A and IL28B. They found that in whole blood, the 
responder haplotype was weakly associated with higher expression levels(8).  Most studies 
have concluded that the SNPs rs12979860 and rs8099917 are associated with reduced IFNλ3 
expression during chronic HCV infection in liver biopsies, serum, and PBMCs(146)(144). 
There are no studies  that has shown a significant increase in IFNλ3 expression due to a SNP 
to best of our knowledge. The SNPs may also affect the function of other genes in the locus. 
These variants have been associated with alteration in serum IFNλ1 and IFNλ2 levels and 
with HCV infection outcomes, both spontaneous resolution and IFN treatment 
responses(121). 
In our study, there was no significant (>0.05) correlation observed between IL-28B 
genotypes and IL-28B plasma level among treatment naïve HIV infected individuals and 
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following 6-9 months of ART. There was no significant (p=>0.05) correlation between IL-
28B haplotypes and the IL-28B plasma level before and after 6-9 months of ART.  
However, out of 49 HIV infected individuals, 8 HIV infected indviduals with CT/GT 
haplotype had a higher median IL-28B plasma levels when compared to other haplotypes 
CC/TT, CT/TT, before initiation of ART.  The median absolute CD4+ T-cell count values of 
these HIV infected were higher as observed with the  CC/TT haplotype which had a 
significant( p=0.03) association with higher CD4+ T-cell counts before initiation of ART. 
There was a significant decrease in IL-28B plasma level following 6-9 months of ART.  
RR Tian et al(2012), reported previously that HIV-1 infected individuals with CD4+ T-cell 
numbers greater than 800 cells/µL retained a similarly level of plasma IFN -λ1 to the 
uninfected controls and IL-λ1 was significantly elevated along with the depletion of CD4+ T-
cells in HIV-1 infected individuals(119). The IFN -λ1 production was dropped when CD4 
numbers were lower than 200/µL (known as the defined AIDS phase) the reason may be due 
to defective cytokine secretion or the persistent depletion of blood myeloid cells, which are 
the main producers of IFN-λ. The same investigators has also shown in vitro that that IFN-
lamda has got an anti viral effect against HIV replication.  However in vivo monitoring 
showed that plasma IL-29 level was  increased along with the depletion of CD4+ T-cells in 
HIV-1 infected patients and the elevated IL-29 showed minimal inhibition of viral 
replication(119). This was also reported with experimental HBV infection among animals  
(109). The same phenomena maybe happening with HIV-1 infected individuals with CT/GT 
haplotype in our study.  
 High levels of IFNλs, but not IFN-α, is also observed during viral infection of lung and liver 
tissues, IFNλs seem to be the major IFNs induced in airway epithelial cells during infection 
with respiratory viruses Influenza A and Respiratory Synctitial virus(189). In our study the 
concurrent respiratory infections in HIV positive individuals were not analyzed. This may be 
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one of the reason for higher IL-28B plasma levels in patients with CT/GT haplotype and the 
reduction in the IL-28B plasma level following ART may be that the ART would have 
resolved the opportunistic respiratory infections following immune reconstitution.   
 
Studies reporting the IL-28B plasma level in healthy individuals are limited.  Pica et al(2010) 
reported the difference PBMC from patients with a history of recurrent Herpes labialis  
produced markedly lower levels of IFN-λ and marginally lower levels of IFN-α and IFN-γ 
than those from the history-negative HSV-1-seropositive controls(190).  
In our study, there was no significant (p = >0.05) difference observed in IL-28B plasma level 
in treatment naïve HIV infected individuals and healthy controls (p= >0.05).   Hence, there is 
no significant correlation between IL-28B polymorphism and IL-28B plasma level among 
treatment naïve HIV infected individuals and following 6-9 months of ART. 
 
Studies reporting the effect of IL-28B on CD4+ T-cell counts are limited. In our study we 
looked at the association of IL-28B level with the CD4+, CD8+ absolute T-cell counts and 
CD4/CD8 ratio. We could not find any significant (>0.05) correlation between IL-28B 
plasma level with absolute CD4+ T-cell counts,  CD4/CD3%, absolute CD8+ T-cell , 
CD8/CD3% and CD4/CD8 ratio among treatment naïve HIV infected individuals and  
following  6-9 months of ART.  
 
In conclusion our preliminary data from this pilot study showed significantly higher CD4+ T-
cells among HIV infected individuals with wild haplotype (CC/TT) prior to ART and 
significantly high CD4+ T cells and CD4/CD3% following ART.  However, this preliminary 
study showed no association of IL-28B polymorphism(s) with IL-28B plasma level and 
CD4+ T cell count or CD4/CD8 ratio.  Since IFN-λ is a powerful immune modulator 
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functional studies are warranted to understand the IFN-λ mediated immunopathogeneis in 
HIV infection. Furthermore studies with larger sample size are required to look at the 
association of   IL-28B polymorphisms with plasma level and IL-28B mRNA expression 
among HIV infected individuals.  
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6. Summary 
 
In this study a total of 80 HIV infected individuals were recruited after taking 
informed consent. Only 49 of the 89 recruited HIV infected individuals were 
followed for 6-10 months after initiation of ART. Among 80 recruited initially 7 
patients expired during the study and 24 patients either did not follow up or were not 
initiated on treatment. 
1) Out of 49 HIV infected individuals 30 were from Tamil Nadu of which 16 were 
males and 14 were females with mean age of 42 years (+ 10). Eighteen were from 
Andhra Pradesh of which 12 were males and 6 were females with mean age of 41 
years (+ 10) and 1 male from Kerala. The 30 age and sex matched HIV negative 
healthy controls recruited were all from Tamil Nadu with mean age 42years( +10). 
2) Among the 49 HIV infected individuals the genotype frequency of the SNP 
rs12979860 C/C genotype was higher 32 (65.3%) compared with 15(30.6%) of C/T 
and 2(4.1%) T/T genotypes. The frequency of SNP rs8099917 T/T genotype was 
higher 39(79.6%) compared with 9(18.4%) of G/T and 1(2%) of G/G genotypes. 
Among the 30 healthy controls the genotype frequency of SNP rs12979860 C/C 
genotype was higher 18(60%) compared with 10(33.3%) of C/T and 2(6.7%) of T/T 
genotypes. The frequency of SNP rs8099917 T/T genotype was 23(76.7%) compared 
with 7(23.3%) of G/T and G/G genotype was not reported. No significant ( p= >0.05) 
differences were found out in the distribution of IL-28B polymorphism at both the 
SNPs between HIV infected individuals and healthy controls. 
3) The above frequency in the distribution of IL-28B genotypes in south Indian 
population is similar to in the one already reported from Andhra Pradesh. The 
frequency reported out of 220 subjects recruited in that study was CC (59.09%), 
CT(34.09) and TT(6.81) for SNP rs12979860. 
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4) The absolute CD4 + and CD8+ T-cells, CD4/CD8 were estimated both during 
recruitment and after 6-9 months of ART. There was a significant increase (p=< 
0.0001 )  in the median  absolute CD4+ T cell count, CD4/CD3% and there was a 
reversal of median CD4/CD8 ratio following 6-9 months of ART among the HIV 
infected studied population. 
5)  There was  a significant(p = 0.03) association of CC genotype at rs12979860  when 
compared to other genotypes(C/T and T/T) with higher CD4+ T-cell count among 
treatment naïve HIV infected individuals and was also significantly (p= 0.05) 
associated with  higher CD4+ T-cell count following 6-9 months of ART 
6) There is a no significant(p = >0.05) association of CC genotype at rs12979860  when 
compared to other minor genotypes(C/T and T/T) with CD8+ T-cell count and 
CD8/CD3% among treatment naïve HIV infected individuals and was also not 
significantly (p= >0.05) associated with increase in CD8+ T-cell count following 6-9 
months of ART 
7) There was a no significant(p = >0.05) association of CC genotype at rs12979860  
when compared to other genotypes(C/T and T/T) with median CD4/CD8 ratio among 
treatment naïve HIV infected individuals and was also not significantly (p= >0.05) 
associated with reversal of CD4/CD8 ratio following 6-9 months of ART. 
8) In contrast to the association seen between the CD4+ T cell count and the wild 
genotype at rs12979860 there was no correlation observed between the genotypes at  
rs8099917 and CD4/CD8 + T-cell counts prior to or following ART.  
9) There was a significant(p=0.03) association of CC/TT haplotype at when compared to 
other haplotypes (CT/GT and CT/TT) with higher CD4+ T-cell count among 
treatment naïve HIV infected individuals and was also significantly (p= 0.05) 
associated with  higher CD4+ T-cell count following 6-9 months of ART. 
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10) There was no significant (p = 0.1) association of CC/TT haplotype when compared to 
other haplotype with higher CD4/CD3% among treatment naïve HIV infected 
individuals, However they were significantly( p = 0.03)  associated with higher 
CD4/CD3% compared to other haplotypes following 6-9 months of ART.  
11) There was  a no significant(p = >0.05) association of haplotypes with CD8+ T-cell 
count  and CD8/CD3% among treatment naïve HIV infected individuals and was also 
not significantly (p= >0.05) associated with change in CD8+ T-cell count and 
decrease in CD8/CD3% following 6-9 months of ART. 
12) There was a no significant(p = >0.05) association of haplotypes with CD4/CD8 ratio 
among treatment naïve HIV infected individuals and was also not significantly (p= 
>0.05) associated with reversal of CD4/CD8 ratio following 6-9 months of ART. 
13) There was no significant (p = >0.05) difference in the median IL-28B plasma level  
among treatment naïve HIV infected individuals and healthy controls 
14) There was  no significant (>0.05) correlation observed between IL-28B plasma level 
with absolute CD4+ T-cell counts and CD4/CD3% among treatment naïve HIV 
infected individuals and following 6-9 months of ART 
15) There was  no significant (>0.05) observed correlation between IL-28B genotypes at 
both rs12979860 & rs8099917  with IL-28B plasma level among treatment naïve HIV 
infected individuals and following 6-9 months of ART. 
16) There was no significant (p=>0.05) correlation observed between IL-28B haplotypes 
between the IL-28B plasma level before and after 6-9 months of ART. 
17) When we looked at the association of the haplotypes and the IL-28B plasma level, we 
found out that the CT/GT haplotype had a significant higher IL-28B plasma level 
compared to wild type CC/TT before the initiation of ART though the median CD4+ 
T-cell counts were almost similar. Following 6-10 months of ART the median 
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decrease observed in CT/GT haplotype compared to CC/TT wild type were 
significant.The reason for this needs to be further investigated. 
18) In conclusion our preliminary data from this pilot study showed significantly higher 
CD4+ T-cells among HIV infected individuals with wild haplotype (CC/TT) prior to 
ART and significantly high CD4+ T cells and CD4/CD3% following ART.  
However, this preliminary study showed no association of IL-28B polymorphism (s) 
with IL-28B plasma level and CD4+ T cell count or CD4/CD8 ratio.  Since IFN is a 
powerful immune modulator functional studies are warranted to understand the IFN 
lambda mediated immuno-pathogeneis in HIV infection. Furthermore studies with 
larger sample size are required to look at the association of  IL-28B polymorphisms 
with  plasma level and IL-28B mRNA expression among HIV infected individuals.  
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Consent Form 
INFORMED CONSENT  
Information sheet 
Title of study – 
“A pilot study to look at the effect of IL-28 polymorphism on IL-28 expression and 
immunological recovery among HIV infected individuals following ART” 
Description of the study 
 HIV is one of the important infections worldwide.  Over 2.4 million people are infected with 
HIV in India which stands 3
rd
 in the world. It is transmitted through unsafe sexual 
intercourse, infected blood and blood products and also from infected mother to the child. 
The disease progresses by destroying the immune system (CD4+ T lymphocytes) in the body 
and thus causes infections by several other microorganisms ultimately leading to death.   
Since there is no permanent cure for HIV infection, it is important to control the disease 
progression with drugs that stop viral multiplication. The Anti-Retroviral Therapy (ART) is 
the only available treatment to control progression.  The response to these drugs is monitored 
through estimation CD4+ and HIV-1 viral load. Cytokines like Interleukin-28 are group of 
proteins which play an important role in the multiplication of virus and progression of 
disease. CD4 + T lymphocytes play an important role in the human body to fight against 
infections.  Experiments have shown that a change in the gene that controls Interleukin-28 
can improve the condition in patients with Hepatitis C infection which infect liver.  In this 
study we are going to look at this change can improve the health condition of HIV infected 
individuals.   
Note : If you are participating as a control (healthy individual) in the study, HIV testing will 
be done prior to recruitment, towards this a separate consent as per national 
guidelines(attached)will be obtained. We will be collecting 8ml of blood towards HIV testing 
, CD4+/CD8+ T-cell count,IL-28 plasma level and IL-28 polymorphism . 
If you are found HIV positive, result will be informed and you will be referred to ID clinic 
for counselling and further management and you will not be part of study. 
Can you withdraw from this study after it starts and during follow up? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. 
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What will happen if you develop any study related injury? 
We do not expect any injury to happen to you if you participate in the study. 
Will you have to pay for the study? 
No  
What amount of sample is collected? 
Extra 5-6ml of blood is collected if you are coming for routine testing 
What happens after the study is over? 
The results obtained from the samples collected will be used only for the study and data may 
publish in scientific journal and the remaining samples will be stored in our laboratory. All 
the details will be kept confidential including the results of the test for HIV.  
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but your identity will not be 
revealed in any publication or presentation of results. 
 
If you have any further questions, please ask Dr.Srinidhi.B.V. (Department of 
Microbiology)(Contact number:+919597557036,email id:newtonnidhi@gmail.com) 
 
 
 
 
 
 
 
 
 
 
 
152 
 
 
                 CONSENT FORM TO TAKE PART IN THE STUDY 
Study title: “A pilot study to look at the effect of IL-28 polymorphism on IL-28 
expression and immunological recovery among HIV infected individuals following 
ART” 
 
Study Number:                                                                                                  Hosp. no: 
Participant’s name:                                      
Date of Birth / Age (in years): 
I_____________________________________________________________ 
___________, son/daughter of  ___________________________________ 
(Please tick boxes) 
Declare that I have read the information sheet provided to me regarding this study and have 
clarified any doubts that I had. [ ] 
I also understand that my participation in this study is entirely voluntary and that I am free to 
withdraw permission to continue to participate at any time without affecting my usual 
treatment or my legal rights [ ] 
I understand that the study staff and institutional ethics committee members will not need my 
permission to look at my health records even if I withdraw from the trial. 
 I agree to this access [ ]  
I understand that my identity will not be revealed in any information released to third parties 
or published [ ]   
I voluntarily agree to take part in this study [ ] 
Would you like to give permission to store the remaining sample in our specimen bank and 
can be used for future studies [YES/NO] 
Healthy individuals, I also understand that sample collected will be tested for HIV [Yes/No] 
Name:                                                                             Name of witness:  
Signature/Thumb impression:                                            Signature of witness: 
Date:                   Relation to participant: 
                   Signature of investigator: 
                   Date:  
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